1
|
Kane D, Gill N, Walshe J, Fallon C, Flood K, Eogan M. Sexual assault of the older person: Attendances to the Republic of Ireland's sexual assault treatment unit network. J Forensic Leg Med 2024; 103:102683. [PMID: 38669956 DOI: 10.1016/j.jflm.2024.102683] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2024] [Accepted: 04/02/2024] [Indexed: 04/28/2024]
Abstract
BACKGROUND Sexual assault (SA) poses a threat to all areas of contemporary society. Although older individuals represent a vulnerable demographic, a considerable gap exists in the literature regarding the context in which older individuals experience SA. This study aims to provide a comprehensive description of older individuals' attendances at the Sexual Assault Treatment Unit (SATU) network in the Republic of Ireland. METHODS A 7-year national cross-sectional study was performed to analyse the attendances of older people (≥65 years old) to the SATU network, and to compare them with younger attendances (<65 years old), with a more in-depth subset analysis of Dublin SATU attendances. RESULTS During the study period, there were 6478 attendances to the SATU network, of which 0.93 % (n = 60) were older people. These included 59 females and 1 male, with the average age of 76.05 years ± 8.16. Forensic examinations were performed in 81.7 %, with the majority seeking assistance within 7 days (80 %). Comparison of older (≥65 years) and younger (<65 years) attendees revealed older individuals were more uncertain whether a sexual assault had occurred (35.5 % vs. 14.4 %, p < 0.001) but more likely to report the incident to the police (78.3 % vs. 64.3 %, p = 0.02). Assault by a person in authority was significantly more common in older age groups (11.7 % vs. 1.8 %, p < 0.001). Older individuals were significantly more likely to be assaulted in their own home (33.3 % vs. 21.5 p < 0.03) or in 'other-indoors' settings (e.g. nursing home/hospital) (43.3 % vs. 23.4 % p < 0.001). They were less likely to be assaulted in the assailant's home (5.0 % vs. 22.9 %, p < 0.001) or outdoors (5.0 % vs. 19.7 %, p = 0.004). In our subset analysis of 19 cases, 73.7 % occurred in healthcare facilities, 63.2 % had dementia, and 42.1 % were care dependent. Genital injuries were present in 44.4 % of patients and extra-genital injuries in 22.2 %. CONCLUSION Unique patterns are evident in sexual assault experienced by older people, underscoring the necessity for tailored interventions and effective support systems for reporting and addressing this vulnerable demographic. This is especially crucial in healthcare environments, where a notable proportion of cases occur, frequently involving individuals with dementia and requiring care assistance.
Collapse
Affiliation(s)
- D Kane
- Department of Obstetrics & Gynaecology, Royal College of Surgeons in Ireland, Rotunda Hospital, Parnell Square, Dublin 1, Ireland; Sexual Assault Treatment Unit, Rotunda Hospital, Dublin 1, Ireland.
| | - N Gill
- Sexual Assault Treatment Unit, Regional Hospital Mullingar, Co. Westmeath, Ireland
| | - J Walshe
- Sexual Assault Treatment Unit, Rotunda Hospital, Dublin 1, Ireland
| | - C Fallon
- Department of Geriatric Medicine, Regional Hospital Mullingar, Co. Westmeath, Ireland
| | - K Flood
- Department of Obstetrics & Gynaecology, Royal College of Surgeons in Ireland, Rotunda Hospital, Parnell Square, Dublin 1, Ireland
| | - M Eogan
- Department of Obstetrics & Gynaecology, Royal College of Surgeons in Ireland, Rotunda Hospital, Parnell Square, Dublin 1, Ireland; Sexual Assault Treatment Unit, Rotunda Hospital, Dublin 1, Ireland
| |
Collapse
|
2
|
Walshe J, Elphinstone B, Nicol D, Taylor M. A systematic literature review of the 'commercialisation effect' on public attitudes towards biobank and genomic data repositories. Public Underst Sci 2024:9636625241230864. [PMID: 38389329 DOI: 10.1177/09636625241230864] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/24/2024]
Abstract
Initiatives that collect and share genomic data to advance health research are widespread and accelerating. Commercial interests in these efforts, while vital, may erode public trust and willingness to provide personal genomic data, upon which these initiatives depend. Understanding public attitudes towards providing genomic data for health research in the context of commercial involvement is critical. A PRISMA-guided search of six online academic databases identified 113 quantitative and qualitative studies using primary data pertaining to public attitudes towards commercial actors in the management, collection, access, and use of biobank and genomic data. The presence of commercial interests yields interrelated public concerns around consent, privacy and data security, trust in science and scientists, benefit sharing, and the ownership and control of health data. Carefully considered regulatory and data governance and access policies are therefore required to maintain public trust and support for genomic health initiatives.
Collapse
|
3
|
Warren V, Critchley C, McWhirter R, Walshe J, Nicol D. Context matters in genomic data sharing: a qualitative investigation into responses from the Australian public. BMC Med Genomics 2023; 15:275. [PMID: 37005651 PMCID: PMC10068139 DOI: 10.1186/s12920-023-01452-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2021] [Accepted: 02/01/2023] [Indexed: 04/04/2023] Open
Abstract
BACKGROUND Understanding public attitudes to genomic data sharing is widely seen as key in shaping effective governance. However, empirical research in this area often fails to capture the contextual nuances of diverse sharing practices and regulatory concerns encountered in real-world genomic data sharing. This study aimed to investigate factors affecting public attitudes to data sharing through responses to diverse genomic data sharing scenarios. METHODS A set of seven empirically validated genomic data sharing scenarios reflecting a range of current practices in Australia was used in an open-ended survey of a diverse sample of the Australian public (n = 243). Qualitative responses were obtained for each of the scenarios. Respondents were each allocated one scenario and asked five questions on: whether (and why/not) they would share data; what sharing would depend on; benefits and risks of sharing; risks they were willing to accept if sharing was certain to result in benefits; and what could increase their comfort about sharing and any potential risk. A thematic analysis was used to examine responses, coded and validated by two blinded coders. RESULTS Participants indicated an overall high willingness to share genomic information, although this willingness varied considerably between different scenarios. A strong perception of benefits was reported as the foremost explanation for willingness to share across all scenarios. The high degree of convergence in the perception of benefits and the types of benefits identified by participants across all the scenarios suggests that the differentiation in intention to share may lie in perceptions of risk, which showed distinct patterns within and between the different scenarios. Some concerns were shared strongly across all scenarios, particularly benefit sharing, future use, and privacy. CONCLUSIONS Qualitative responses provide insight into popular assumptions regarding existing protections, conceptions of privacy, and which trade-offs are generally acceptable. Our results indicate that public attitudes and concerns are heterogeneous and influenced by the context in which sharing takes place. The convergence of key themes such as benefits and future uses point to core concerns that must be centred in regulatory responses to genomic data sharing.
Collapse
Affiliation(s)
- Vanessa Warren
- School of Law, University of Tasmania, Sandy Bay, TAS, Australia.
| | - Christine Critchley
- School of Law, University of Tasmania, Sandy Bay, TAS, Australia
- School of Health Science, Swinburne University of Technology, Hawthorn, VIC, Australia
| | - Rebekah McWhirter
- School of Law, University of Tasmania, Sandy Bay, TAS, Australia
- School of Medicine, Deakin University, Waurn Ponds, VIC, Australia
| | - Jarrod Walshe
- School of Health Science, Swinburne University of Technology, Hawthorn, VIC, Australia
| | - Dianne Nicol
- School of Law, University of Tasmania, Sandy Bay, TAS, Australia
| |
Collapse
|
4
|
Walshe J, Doran J, Amarandei G. Evaluation of the potential of nanofluids containing different Ag nanoparticle size distributions for enhanced solar energy conversion in hybrid photovoltaic-thermal (PVT) applications. Nano Ex 2022. [DOI: 10.1088/2632-959x/ac49f2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
Abstract
Hybridising photovoltaic and photothermal technologies into a single system that can simultaneously deliver heat and power represents one of the leading strategies for generating clean energy at more affordable prices. In a hybrid photovoltaic-thermal (PVT) system, the capability to modulate the thermal and electrical power output is significantly influenced by the spectral properties of the heat transfer fluid utilised. In this study, we report on one of the first experimental evaluations of the capability of a multimodal silver nanofluid containing various particle shapes and particle sizes to selectively modulate the solar energy for PVT applications. The diverse set of particle properties led up to a 50.4% enhancement in the solar energy absorbed by the nanofluid over the 300 nm—550 nm spectral region, where silicon is known to exhibit poor photovoltaic conversion performances. This improved substantially the absorption of solar energy, with an additional 18–129 W m−2 of thermal power being generated by the PVT system. Along with the advancements made in the thermal power output of the PVT system, a decrease of 4.7–36.6 W m−2 in the electrical power generated by the photovoltaic element was noted. Thus, for every ∼11 W m−2 increase of thermal power achieved through the addition of the nanoparticles, a reduction of ∼3 W m−2 in the ability to generate clean electricity was sustained by the PVT. Despite the energy trade-offs involved under the conditions of the nanofluid, the PVT system cumulatively harvested 405 W m−2 of solar energy, which amounts to a total conversion efficiency of 45%. Furthermore, the economics of the additional energy harvested through merging of the two systems was found to reach an enhancement of 77% under certain European conditions.
Collapse
|
5
|
Chew S, Reilly A, Brady M, Kamel D, McDermott R, Walshe J, McCaffrey J, Kelly C. 20P Next generation sequencing and associated treatment changes: Results from Ireland East Hospital Group. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.2179] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
6
|
Skrobo D, Walsh N, Quinn C, Walshe J, Smyth L, Gullo G, Crown J. 173P Clinical characteristics of long-term responders to anti-HER2 therapy in metastatic breast cancer: A review of the charactHER clinical data. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.03.273] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
7
|
Swinton-Bland BMA, Hinde DJ, Dasgupta M, Jeung DY, Williams E, Cook KJ, Prasad E, Rafferty DC, Sengupta C, Simenel C, Simpson EC, Smith JF, Vo-Phuoc K, Walshe J. Systematic Study of Quasifission in 48Ca-induced reactions. EPJ Web Conf 2020. [DOI: 10.1051/epjconf/202023203007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
The production of superheavy elements through the fusion of two heavy nuclei is severely hindered by the quasifission process, which results in the fission of heavy systems before an equilibrated compound nucleus (CN) can be formed. The heaviest elements have been synthesised using 48Ca as the projectile nucleus. However, the use of 48Ca in the formation of new superheavy elements has been exhausted, thus a detailed understanding of the properties that made 48Ca so successful is required. Measurements of mass-angle distributions allow fission fragment mass distribution widths to be determined. The effect of the orientation of prolate deformed target nuclei is presented. Closed shells in the entrance channel are also shown to be more important than the stability of the formed CN in reducing the quasifission component, with reduced mass widths for reactions with the closed shell target nuclei 144Sm and 208Pb. Comparison to mass widths for 48Ti-induced reactions show a significant increase in the mass width compared to 48Ca-induced reactions, highlighting the difficulty faced in forming new superheavy elements using projectiles with higher atomic number than 48Ca.
Collapse
|
8
|
Banerjee K, Hinde DJ, Dasgupta M, Simpson EC, Jeung DY, Simenel C, Swinton-Bland BMA, Williams E, Carter IP, Cook KJ, David HM, Düllmann CE, Khuyagbaatar J, Kindler B, Lommel B, Prasad E, Sengupta C, Smith JF, Vo-Phuoc K, Walshe J, Yakushev A. Mechanisms Suppressing Superheavy Element Yields in Cold Fusion Reactions. Phys Rev Lett 2019; 122:232503. [PMID: 31298876 DOI: 10.1103/physrevlett.122.232503] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/13/2018] [Revised: 10/17/2018] [Indexed: 06/10/2023]
Abstract
Superheavy elements are formed in fusion reactions which are hindered by fast nonequilibrium processes. To quantify these, mass-angle distributions and cross sections have been measured, at beam energies from below-barrier to 25% above, for the reactions of ^{48}Ca, ^{50}Ti, and ^{54}Cr with ^{208}Pb. Moving from ^{48}Ca to ^{54}Cr leads to a drastic fall in the symmetric fission yield, which is reflected in the measured mass-angle distribution by the presence of competing fast nonequilibrium deep inelastic and quasifission processes. These are responsible for reduction of the compound nucleus formation probablity P_{CN} (as measured by the symmetric-peaked fission cross section), by a factor of 2.5 for ^{50}Ti and 15 for ^{54}Cr in comparison to ^{48}Ca. The energy dependence of P_{CN} indicates that cold fusion reactions (involving ^{208}Pb) are not driven by a diffusion process.
Collapse
Affiliation(s)
- K Banerjee
- Department of Nuclear Physics, Research School of Physics and Engineering, The Australian National University, Canberra ACT 2601, Australia
| | - D J Hinde
- Department of Nuclear Physics, Research School of Physics and Engineering, The Australian National University, Canberra ACT 2601, Australia
| | - M Dasgupta
- Department of Nuclear Physics, Research School of Physics and Engineering, The Australian National University, Canberra ACT 2601, Australia
| | - E C Simpson
- Department of Nuclear Physics, Research School of Physics and Engineering, The Australian National University, Canberra ACT 2601, Australia
| | - D Y Jeung
- Department of Nuclear Physics, Research School of Physics and Engineering, The Australian National University, Canberra ACT 2601, Australia
| | - C Simenel
- Department of Nuclear Physics, Research School of Physics and Engineering, The Australian National University, Canberra ACT 2601, Australia
| | - B M A Swinton-Bland
- Department of Nuclear Physics, Research School of Physics and Engineering, The Australian National University, Canberra ACT 2601, Australia
| | - E Williams
- Department of Nuclear Physics, Research School of Physics and Engineering, The Australian National University, Canberra ACT 2601, Australia
| | - I P Carter
- Department of Nuclear Physics, Research School of Physics and Engineering, The Australian National University, Canberra ACT 2601, Australia
| | - K J Cook
- Department of Nuclear Physics, Research School of Physics and Engineering, The Australian National University, Canberra ACT 2601, Australia
| | - H M David
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
| | - Ch E Düllmann
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
- Helmholtz Institute Mainz, 55099 Mainz, Germany
- Institut für Kernchemie, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - J Khuyagbaatar
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
- Helmholtz Institute Mainz, 55099 Mainz, Germany
| | - B Kindler
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
| | - B Lommel
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
| | - E Prasad
- Department of Nuclear Physics, Research School of Physics and Engineering, The Australian National University, Canberra ACT 2601, Australia
| | - C Sengupta
- Department of Nuclear Physics, Research School of Physics and Engineering, The Australian National University, Canberra ACT 2601, Australia
| | - J F Smith
- Department of Nuclear Physics, Research School of Physics and Engineering, The Australian National University, Canberra ACT 2601, Australia
| | - K Vo-Phuoc
- Department of Nuclear Physics, Research School of Physics and Engineering, The Australian National University, Canberra ACT 2601, Australia
| | - J Walshe
- Department of Nuclear Physics, Research School of Physics and Engineering, The Australian National University, Canberra ACT 2601, Australia
| | - A Yakushev
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
- Helmholtz Institute Mainz, 55099 Mainz, Germany
| |
Collapse
|
9
|
Critchley C, Nicol D, Bruce G, Walshe J, Treleaven T, Tuch B. Predicting Public Attitudes Toward Gene Editing of Germlines: The Impact of Moral and Hereditary Concern in Human and Animal Applications. Front Genet 2019; 9:704. [PMID: 30687386 PMCID: PMC6334182 DOI: 10.3389/fgene.2018.00704] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2018] [Accepted: 12/14/2018] [Indexed: 01/31/2023] Open
Abstract
Background and Objective: New and more efficient methods of gene editing have intensified the ethical and legal issues associated with editing germlines. Yet no research has separated the impact of hereditary concern on public attitudes from moral concern. This research compares the impact these two concerns have on public attitudes across five applications including, the prevention of human disease, human and animal research, animals for the use of human food and the enhancement of human appearance. Methods: A sample of 1004 Australians responded to either a telephone (n = 501; randomly selected) or online survey (n = 503; sourced by Qualtrics). Both samples were representative in terms of States and Territories as well as gender (51% female), though the online sample was younger (M = 40.64, SD = 16.98; Range = 18–87) than the telephone sample (M = 54.79, SD = 18.13; Range = 18–96). A 5 (application) by 3 (type of cell) within groups design was utilized, where all respondents reported their level of approval with scientists editing genes across the 15 different contexts. Multilevel modeling was used to examine the impact of moral (embryo vs. germ) and hereditary (germ vs. somatic) concern on attitudes across all applications. Results: Australians were comfortable with editing human and animal embryos, but only for research purposes and to enhance human health. The effect of moral concern was stronger than hereditary concern, existing in all applications except for the use of animals for human purposes. Hereditary concern was only found to influence attitudes in two applications: improving human health and human research. Moral concern was found to be accentuated amongst, women, more religious individuals and those identifying as Australian, while hereditary concern was strongest amongst non-Australians, those with stronger trust in scientists, and more religious respondents. Conclusion: Moral and hereditary concerns are distinct, and require different approaches to public education, engagement and possibly regulation. Further research needs to explore hereditary concern in relation to non-human applications, and the reasons underlying cultural and gender differences.
Collapse
Affiliation(s)
- Christine Critchley
- Centre for Law and Genetics, School of Law, University of Tasmania, Hobart, TAS, Australia.,Department of Statistics, Data Science and Epidemiology, Swinburne University of Technology, Melbourne, VIC, Australia
| | - Dianne Nicol
- Centre for Law and Genetics, School of Law, University of Tasmania, Hobart, TAS, Australia
| | - Gordana Bruce
- Department of Statistics, Data Science and Epidemiology, Swinburne University of Technology, Melbourne, VIC, Australia
| | - Jarrod Walshe
- Department of Statistics, Data Science and Epidemiology, Swinburne University of Technology, Melbourne, VIC, Australia
| | - Tamara Treleaven
- Discipline of Physiology, Faculty of Medicine and Health, School of Medical Sciences, The University of Sydney, Sydney, NSW, Australia
| | - Bernard Tuch
- Discipline of Physiology, Faculty of Medicine and Health, School of Medical Sciences, The University of Sydney, Sydney, NSW, Australia
| |
Collapse
|
10
|
Keegan N, Toomey S, Farrelly A, Carr A, Calzaferri G, Walshe J, Gullo G, Crown J, Egan K, Hernando A, Teiserskiene A, Grogan L, Breathnach O, Morris P, Hennessy B. Monitoring the effect of PI3K inhibition on HER2 therapy resistant breast cancer using serial analysis of PIK3CA mutant tumour DNA in plasma. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy269.136] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
11
|
Flynn C, Gullo G, Walshe J, O’doherty A, Fennelly D, Mcdermott E, Crown J. Use of contrast-enhanced Magnetic Resonance Imaging (MRI) to predict pathological response after trastuzumab (T) – based neoadjuvant chemotherapy (NAC) for HER2-positive breast cancer (HER2BrCa). Eur J Cancer 2018. [DOI: 10.1016/s0959-8049(18)30477-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
12
|
Gennari A, Sun Z, Hasler-Strub U, Colleoni M, Kennedy M, Von Moos R, Cortés J, Vidal M, Hennessy B, Walshe J, Parraga KA, Ribi K, Bernhard J, Murillo SM, Pagani O, Barbeaux A, Borstnar S, Rabaglio-Poretti M, Maibach R, Regan M, Jerusalem G. A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial. Ann Oncol 2018; 29:661-668. [DOI: 10.1093/annonc/mdx772] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
13
|
Gullo G, Walsh N, Fennelly D, Walshe J, O'Mahony K, Silva N, Ballot J, Calzaferri G, Quinn C, McDonnell D, Crown J. Abstract P5-20-05: Impact of type of (neo)adjuvant systemic therapy (AdjTx) and total exposure to trastuzumab (TET) on long-term outcome of HER2-positive (HER2+) early stage breast cancer (ESBrCa). Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p5-20-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Trastuzumab (T) administered for 12 months (mos) as part of a taxane (Tax)– or Tax+anthracycline (Anthra)–based AdjTx is the standard of care as (neo)AdjTx of HER2+ ESBrCa. Several prospective randomized trials have investigated a shorter duration of Adj T (i.e. 9 weeks or 6 mos) compared to standard 12 mos of T. However, the results have not been conclusive so far. The impact of administering non-Tax/non-Anthra-based AdjTx and single-agent T on long-term outcome of HER2+ ESBrCa is not fully known.
Methods
We conducted a retrospective analysis on a prospectively maintained departmental database of all patients (pts) with Stage I-III HER2+ ESBrCa treated with at least one dose of (neo)Adj T. Pre-planned duration of T was 12 mos for all pts. TTE was defined as the interval in weeks between the first and the last dose of T. In order to ensure that most pts had a minimum FU of 3 yrs we included all pts who received 1st T before March 31st 2014. The database was locked for outcome analyses on March 31st 2017.
Results
506 pts treated between October 2001 and March 2014 were included in the study. Main pts characteristics: median age: 55 years (range: 26-85), oestrogen (ER) and/or progesterone (PR) receptors positive: 321 (63%), axillary lymph nodes positive: 266 (52%), Adj T: 386 (76%), neoAdj T: 120 (24%), Tax- and Tax/Anthra–based AdjTx: 457 (90%), non-Tax/non-Anthra AdjTx and single-agent T (without chemotherapy): 49 (10%). Median FU is 73.3 months (range: 1.4-176.3). In the overall population, DFS and OS rates are 83% and 91%, respectively. Pts treated with non-Tax/non-Anthra AdjTx had a significantly higher risk of BrCa relapse [DFS: HR 3.54 (95%CI:1.24 to 10.06, p=0.018)], and death [OS: HR 2.73 (95%CI:0.63 to 11.77 p=0.176)] compared to those treated with Tax–based AdjTx (e.g. TCH [docetaxel/carboplatin/T]). Pts who received single-agent T also had highly significantly worse DFS [HR 4.21 (95%CI:2.18 to 8.38, p<0.0001)] and OS [HR 6.75 (95%CI:3.13 to 14.6 p=<0.0001)] compared to those treated with Tax-based AdjTx. When adjusted for age (<55 vs >55 yrs), the detrimental impact of type of AdjTx remained highly statistically significant (p<0.0001). Patients with TTE<24 weeks had a highly significantly worse DFS [HR 4.7 (95%CI:2.34-9.47, p<0.0001)] and OS [HR 5.36 (95%CI:2.39-12.01, p<0.0001)] compared to pts with TTE>24weeks. In most cases, shorter duration of T was due to reduction in LVEF or patients refusal. In the multivariate model, positive lymph nodes, type of (neo)AdjTx and TET (<24 weeks vs >24 weeks) remained all significant and independent variables associated with worse DFS and OS.
Conclusions
Our mature results indicate that the administration of non-Tax/non-Anthra-based AdjTx and single-agent T is associated with a significant increase in the risk of disease relapse and death and should not be considered as therapeutic options for pts with HER2+ ESBrCa. The administration of T for <24weeks irrespective of the type of AdjTx is also associated with significantly worse outcome.
Citation Format: Gullo G, Walsh N, Fennelly D, Walshe J, O'Mahony K, Silva N, Ballot J, Calzaferri G, Quinn C, McDonnell D, Crown J. Impact of type of (neo)adjuvant systemic therapy (AdjTx) and total exposure to trastuzumab (TET) on long-term outcome of HER2-positive (HER2+) early stage breast cancer (ESBrCa) [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P5-20-05.
Collapse
Affiliation(s)
- G Gullo
- St Vincent's University Hospital, Dublin, Ireland; University College Dublin - School of Medicine, Dublin, Ireland; National Institute for Cellular Biotechnology, Dublin, Ireland; St Vincent's Private Hospital, Dublin, Ireland; Cancer Clinical Research Trust, Dublin, Ireland
| | - N Walsh
- St Vincent's University Hospital, Dublin, Ireland; University College Dublin - School of Medicine, Dublin, Ireland; National Institute for Cellular Biotechnology, Dublin, Ireland; St Vincent's Private Hospital, Dublin, Ireland; Cancer Clinical Research Trust, Dublin, Ireland
| | - D Fennelly
- St Vincent's University Hospital, Dublin, Ireland; University College Dublin - School of Medicine, Dublin, Ireland; National Institute for Cellular Biotechnology, Dublin, Ireland; St Vincent's Private Hospital, Dublin, Ireland; Cancer Clinical Research Trust, Dublin, Ireland
| | - J Walshe
- St Vincent's University Hospital, Dublin, Ireland; University College Dublin - School of Medicine, Dublin, Ireland; National Institute for Cellular Biotechnology, Dublin, Ireland; St Vincent's Private Hospital, Dublin, Ireland; Cancer Clinical Research Trust, Dublin, Ireland
| | - K O'Mahony
- St Vincent's University Hospital, Dublin, Ireland; University College Dublin - School of Medicine, Dublin, Ireland; National Institute for Cellular Biotechnology, Dublin, Ireland; St Vincent's Private Hospital, Dublin, Ireland; Cancer Clinical Research Trust, Dublin, Ireland
| | - N Silva
- St Vincent's University Hospital, Dublin, Ireland; University College Dublin - School of Medicine, Dublin, Ireland; National Institute for Cellular Biotechnology, Dublin, Ireland; St Vincent's Private Hospital, Dublin, Ireland; Cancer Clinical Research Trust, Dublin, Ireland
| | - J Ballot
- St Vincent's University Hospital, Dublin, Ireland; University College Dublin - School of Medicine, Dublin, Ireland; National Institute for Cellular Biotechnology, Dublin, Ireland; St Vincent's Private Hospital, Dublin, Ireland; Cancer Clinical Research Trust, Dublin, Ireland
| | - G Calzaferri
- St Vincent's University Hospital, Dublin, Ireland; University College Dublin - School of Medicine, Dublin, Ireland; National Institute for Cellular Biotechnology, Dublin, Ireland; St Vincent's Private Hospital, Dublin, Ireland; Cancer Clinical Research Trust, Dublin, Ireland
| | - C Quinn
- St Vincent's University Hospital, Dublin, Ireland; University College Dublin - School of Medicine, Dublin, Ireland; National Institute for Cellular Biotechnology, Dublin, Ireland; St Vincent's Private Hospital, Dublin, Ireland; Cancer Clinical Research Trust, Dublin, Ireland
| | - D McDonnell
- St Vincent's University Hospital, Dublin, Ireland; University College Dublin - School of Medicine, Dublin, Ireland; National Institute for Cellular Biotechnology, Dublin, Ireland; St Vincent's Private Hospital, Dublin, Ireland; Cancer Clinical Research Trust, Dublin, Ireland
| | - J Crown
- St Vincent's University Hospital, Dublin, Ireland; University College Dublin - School of Medicine, Dublin, Ireland; National Institute for Cellular Biotechnology, Dublin, Ireland; St Vincent's Private Hospital, Dublin, Ireland; Cancer Clinical Research Trust, Dublin, Ireland
| |
Collapse
|
14
|
Ribi K, Sun Z, Jerusalem G, Hasler-Strub U, Colleoni M, von Moos R, Cortés J, Vidal M, Hennessy B, Walshe J, Amillano Parraga K, Morales Muriilo S, Pagani O, Barbeaux A, Bortsnar S, Maibach R, Regan MM, Gennari A, Bernhard J. Abstract P5-18-02: Nab-Paclitaxel-based therapy in the first line treatment of metastatic breast cancer (IBCSG 42-12/BIG 2-12 SNAP): Impact of different schedules on quality of life. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p5-18-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The randomized phase II SNAP trial assessed three alternative reduced maintenance chemotherapy regimens using nab-Paclitaxel after a short term induction phase at conventional doses as first line treatment in patients (pts) with metastatic breast cancer (MBC). For all three regimens median progression-free survival was greater than achieved with full dose docetaxel (historical reference). Symptom palliation and quality of life (QoL) are important when deciding on therapeutic agents and schedules in MBC pts.
Methods: Of the 258 pts with MBC enrolled from April 2013 to August 2015 in the SNAP trial, 255 were included in the QoL analysis. Pts were randomized to three arms, each receiving the same induction chemotherapy based on 3 cycles of nab-Paclitaxel 150 mg/m2 dd 1, 8, 15 Q28, which was reduced to 125 mg/m2 after a safety review. The schedules of nab-Paclitaxel in maintenance therapy differed in each arm: Arm A) 150 mg/m2 dd 1,15 Q28; Arm B) 100 mg/m2 dd 1,8,15 Q28; Arm C) 75 mg/m2 dd 1,8,15,22 Q28. Pts completed a QoL form to assess global and symptom-specific indicators (range 0-100) at baseline, and at day 1 of every cycle for the first 12 cycles on treatment, or until treatment discontinuation. Changes in QoL scores during induction (day 1 cycle 4 − baseline) and maintenance (day 1 cycle 12 – day 1 cycle 4) therapy were summarized descriptively per arm. Treatment effects on changes in QoL during maintenance therapy were analyzed by repeated measurement models including timepoints (from day 1 of cycle 4 to day 1 of cycle 12), induction start dose, age, and treatment arms as covariates.
Results: During induction therapy, mean changes [SD] in hair loss (Arm A:−70.2 [41.9]; Arm B: −77.3 [34.5]; Arm C: −72.6 [32.8]), sensory neuropathy (Arm A: −19.0 [25.2]; Arm B: −20.6 [22.7]; Arm C: −18.8 [23.8]), and treatment burden (Arm A: −12.9 [33.4]; Arm B: −13.4 [33.5]; Arm C: −11.4 [34.8]) showed the most pronounced worsening. During maintenance therapy, scores for sensory neuropathy remained impaired without worsening. No significant differences in changes for sensory neuropathy or the other symptoms were seen between arms, except for hair loss, with pts in arm C (mean difference 10.91; 95% CI [0.35, 21.48]; p=0.04) ] and B (mean difference 18.55; 95% CI [7.52, 29.59]; p=0.001) reporting a greater improvement compared to those in arm A. Pts in arm C reported a significantly greater improvement in mood compared to arm A (mean difference 13.34; 95% CI [6.08, 20.60]; p<0.001) and arm B (mean difference 9.62; 95% CI [2.84, 16.40]; p=0.01)].
Conclusion: The effectiveness of alternative maintenance chemotherapy schedules with reduced doses after a short term induction phase at conventional doses must be weighed against a substantial worsening in sensory neuropathy during induction therapy, and scores continuing to be impaired without worsening with prolonged administration. During maintenance therapy, improvements were seen in the perception of hair loss and in mood, particularly in Arm B and C, with a similar tendency seen for some other QoL domains. A more frequent administration of reduced dose chemotherapy agents is favorable with respect to QoL in this setting.
Citation Format: Ribi K, Sun Z, Jerusalem G, Hasler-Strub U, Colleoni M, von Moos R, Cortés J, Vidal M, Hennessy B, Walshe J, Amillano Parraga K, Morales Muriilo S, Pagani O, Barbeaux A, Bortsnar S, Maibach R, Regan MM, Gennari A, Bernhard J. Nab-Paclitaxel-based therapy in the first line treatment of metastatic breast cancer (IBCSG 42-12/BIG 2-12 SNAP): Impact of different schedules on quality of life [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P5-18-02.
Collapse
Affiliation(s)
- K Ribi
- International Breast Cancer Study Group, Cancer Trials Ireland, and SOLTI
| | - Z Sun
- International Breast Cancer Study Group, Cancer Trials Ireland, and SOLTI
| | - G Jerusalem
- International Breast Cancer Study Group, Cancer Trials Ireland, and SOLTI
| | - U Hasler-Strub
- International Breast Cancer Study Group, Cancer Trials Ireland, and SOLTI
| | - M Colleoni
- International Breast Cancer Study Group, Cancer Trials Ireland, and SOLTI
| | - R von Moos
- International Breast Cancer Study Group, Cancer Trials Ireland, and SOLTI
| | - J Cortés
- International Breast Cancer Study Group, Cancer Trials Ireland, and SOLTI
| | - M Vidal
- International Breast Cancer Study Group, Cancer Trials Ireland, and SOLTI
| | - B Hennessy
- International Breast Cancer Study Group, Cancer Trials Ireland, and SOLTI
| | - J Walshe
- International Breast Cancer Study Group, Cancer Trials Ireland, and SOLTI
| | - K Amillano Parraga
- International Breast Cancer Study Group, Cancer Trials Ireland, and SOLTI
| | - S Morales Muriilo
- International Breast Cancer Study Group, Cancer Trials Ireland, and SOLTI
| | - O Pagani
- International Breast Cancer Study Group, Cancer Trials Ireland, and SOLTI
| | - A Barbeaux
- International Breast Cancer Study Group, Cancer Trials Ireland, and SOLTI
| | - S Bortsnar
- International Breast Cancer Study Group, Cancer Trials Ireland, and SOLTI
| | - R Maibach
- International Breast Cancer Study Group, Cancer Trials Ireland, and SOLTI
| | - MM Regan
- International Breast Cancer Study Group, Cancer Trials Ireland, and SOLTI
| | - A Gennari
- International Breast Cancer Study Group, Cancer Trials Ireland, and SOLTI
| | - J Bernhard
- International Breast Cancer Study Group, Cancer Trials Ireland, and SOLTI
| |
Collapse
|
15
|
Prior L, Teo M, Greally M, Ward C, O'Leary C, Aslam R, Darwish W, Ahmed N, Watson G, Kelly D, Kiely L, Hassan A, Gleeson J, Featherstone H, Lim M, Murray H, Gallagher D, Westrup J, Hennessy B, Leonard G, Grogan L, Breathnach O, Horgan A, Coate L, O'Mahony D, Coate L, O'Reilly S, Gupta R, Keane M, Duffy K, O'Connor M, Kennedy J, McCaffrey J, Higgins M, Kelly C, Carney D, Gullo G, Crown J, Walshe J. Abstract P6-08-17: Pregnancy associated breast cancer: Evaluating maternal outcomes. A multicentre study. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p6-08-17] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Pregnancy associated breast cancer (PABC) is defined as breast cancer (BC) diagnosed during the gestational period (GP) or in the first year postpartum (PP). Despite its infrequent occurrence, the incidence of PABC appears to be rising due to the increasing propensity for women to delay childbirth. We have established the first combined prospective and retrospective registry study of PABC in Ireland to examine specific clinicopathological characteristics, treatments and maternal outcomes. We present the retrospective findings to date.
Methods
We performed a retrospective multicentre observational study of patients (pts) with PABC treated in the eight Irish cancer centres from August 2001 to March 2017. Data extracted included information on pt demographics, tumour biology, staging, treatment administered and maternal outcomes. Standard biostatistical methods were used for analysis.
Results
111 PABC patients were identified. Sixty pts (54%) were diagnosed during the GP and 51 (46%) within 1 year PP. Median age at diagnosis was 36 years (yrs). Table 1 illustrates baseline characteristics. Two thirds of pts were node positive and a similar proportion had grade 3 pathology. Seventy pts (63%) were estrogen receptor (ER) positive, 36 (32%) HER2 positive, 25 (22%) triple negative. Twenty-two pts (20%) were metastatic at presentation. Seven pts (6%) had a known BRCA 1/2 mutation. The median OS (overall survival) and DFS (disease free survival) for the entire cohort was 107.4 and 94.2 months respectively (resp). There was no survival difference between those diagnosed during the GP versus PP. 5 yr DFS and OS was 68.6% and 69.2% resp. This compares unfavourably to results reported by the National Cancer Registry of Ireland in a similar age-matched BC population between 2000-2012 where the 5 yr OS was 86.5%. Variables in our study associated with poorer outcomes included younger age, tumour size, node positivity and lack of estrogen expression.
Baseline characteristics PABC patients (n=11) %(n)Diagnosed in GP (n=60) %(n)Diagnosed 1yr PP (n=51) %(n)p valueDemographic Age at diagnosis3636(25-49)36(21-44)0.31Stage I-II54(60)55(33)53(27)0.85III23(26)23(14)23(12)1IV20(22)18(11)22(11)0.81Unknown3(3)3(2)2(1)1Pathology Grade 366(74)70(42)63(32)0.43Node positive66(73)68(41)63(32)0.55ER+/HER2-41(45)38(23)43(22)0.69ER+/HER2+23(25)28(17)16(8)0.17ER-/HER2+14(16)17(10)12(6)0.59Triple negative22(25)17(10)29(15)0.11Surgery Breast conservation23(26)25(15)21(11)0.82Mastectomy56(63)57(34)59(30)0.84Adjuavnt/Neoadjuvant treatment Chemotherapy73(81)77(46)69(35)0.39Anthracycline68(55)78(36)54(19)0.03Taxane89(72)93(43)83(29)0.16Anti HER2 agent21(23)18(11)24(12)0.63Endocrine therapy64(52)63(29)66(23)0.84Radiotherapy79(64)74(34)86(30)0.85Relapse in Stage I-III Local relapse15(13)12(6)18(7)0.55Distant relapse24(21)22(11)25(10)0.80
Conclusions
PABC patients may have a poorer outcome. Our study reported higher rates of triple negative and HER2 positive breast cancer which are associated with more aggressive biology. Prospective evaluation of clinicopathological features, pharmacokinetics of treatments selected and maternal and fetal outcomes is imperative in this distinct pt group.
Citation Format: Prior L, Teo M, Greally M, Ward C, O'Leary C, Aslam R, Darwish W, Ahmed N, Watson G, Kelly D, Kiely L, Hassan A, Gleeson J, Featherstone H, Lim M, Murray H, Gallagher D, Westrup J, Hennessy B, Leonard G, Grogan L, Breathnach O, Horgan A, Coate L, O'Mahony D, Coate L, O'Reilly S, Gupta R, Keane M, Duffy K, O'Connor M, Kennedy J, McCaffrey J, Higgins M, Kelly C, Carney D, Gullo G, Crown J, Walshe J. Pregnancy associated breast cancer: Evaluating maternal outcomes. A multicentre study [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P6-08-17.
Collapse
Affiliation(s)
- L Prior
- Cancer Trials Ireland, Dublin, Ireland
| | - M Teo
- Cancer Trials Ireland, Dublin, Ireland
| | - M Greally
- Cancer Trials Ireland, Dublin, Ireland
| | - C Ward
- Cancer Trials Ireland, Dublin, Ireland
| | - C O'Leary
- Cancer Trials Ireland, Dublin, Ireland
| | - R Aslam
- Cancer Trials Ireland, Dublin, Ireland
| | - W Darwish
- Cancer Trials Ireland, Dublin, Ireland
| | - N Ahmed
- Cancer Trials Ireland, Dublin, Ireland
| | - G Watson
- Cancer Trials Ireland, Dublin, Ireland
| | - D Kelly
- Cancer Trials Ireland, Dublin, Ireland
| | - L Kiely
- Cancer Trials Ireland, Dublin, Ireland
| | - A Hassan
- Cancer Trials Ireland, Dublin, Ireland
| | - J Gleeson
- Cancer Trials Ireland, Dublin, Ireland
| | | | - M Lim
- Cancer Trials Ireland, Dublin, Ireland
| | - H Murray
- Cancer Trials Ireland, Dublin, Ireland
| | | | - J Westrup
- Cancer Trials Ireland, Dublin, Ireland
| | | | - G Leonard
- Cancer Trials Ireland, Dublin, Ireland
| | - L Grogan
- Cancer Trials Ireland, Dublin, Ireland
| | | | - A Horgan
- Cancer Trials Ireland, Dublin, Ireland
| | - L Coate
- Cancer Trials Ireland, Dublin, Ireland
| | | | - L Coate
- Cancer Trials Ireland, Dublin, Ireland
| | | | - R Gupta
- Cancer Trials Ireland, Dublin, Ireland
| | - M Keane
- Cancer Trials Ireland, Dublin, Ireland
| | - K Duffy
- Cancer Trials Ireland, Dublin, Ireland
| | | | - J Kennedy
- Cancer Trials Ireland, Dublin, Ireland
| | | | - M Higgins
- Cancer Trials Ireland, Dublin, Ireland
| | - C Kelly
- Cancer Trials Ireland, Dublin, Ireland
| | - D Carney
- Cancer Trials Ireland, Dublin, Ireland
| | - G Gullo
- Cancer Trials Ireland, Dublin, Ireland
| | - J Crown
- Cancer Trials Ireland, Dublin, Ireland
| | - J Walshe
- Cancer Trials Ireland, Dublin, Ireland
| |
Collapse
|
16
|
Keegan NM, Walshe J, Gullo G, Kennedy J, Bulger K, Kelly CM, Crown J, Toomey S, Egan K, Kerr J, Given M, Hernando A, Teiserskiene A, Grogan L, Breathnach O, Morris PG, Keane M, Hennessy BT. Abstract OT3-06-05: A phase Ib/II trial of coPANlisib in combination with tratuzumab in pretreated recurrent or metastatic HER2-positive breast cancer “PantHER”. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-ot3-06-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
The phosphoinositide 3 kinase (PI3K) pathway is important in the oncogenic function of HER2. Aberrent activation of PI3K is implicated in resistance to trastuzumab and other HER2-targeted therapies and is frequent, with up to 22% of HER2 positive breast cancer having a PIK3CA mutation. Copanlisib is a pan-class 1 PI3K inhibitor that shows particular activity against PI3Kα, the isoform encoded by the PIK3CA gene. Copanlisib has been shown to re-sensitise trastuzumab resistant cell lines to trastuzumab with synergism seen in some cell lines between copanlisib and HER2 targeted therapy.
Trial design
The study is a phase Ib/II open label, single arm adaptive, multi-centre trial of copanlisib in combination with trastuzumab. Eligible patients are treated with a dose escalation schedule of copanlisib IV on Days 1, 8 and 15 of a 28 day cycle with trastuzumab 2 mg/kg weekly (loading dose of 4 mg/kg in cycle 1). The phase II dose will be based on the maximum tolerated dose (MTD) established in Phase Ib. Patients are treated until radiologic or symptomatic progression, unacceptable toxicity, consent withdrawal or physician's decision.
Eligibility criteria
Eligible patients must have recurrent incurable or metastatic HER2-positive breast cancer that has progressed on at least one prior line of trastuzumab or T-DM1-based treatment regimen in this setting. Patients with treated and controlled brain metastases are eligible. Participants must have adequate organ function and ECOG PS ≤ 2. Patients recruited for the Phase II part of the study must have a PIK3CA mutation. Patients with uncontrolled arterial hypertension, uncontrolled diabetes or recent clinically serious infections are excluded.
Specific aims
The primary end point for the phase Ib part of this study is to determine the MTD for the combination. For the phase II study is anti-tumour efficacy, measured by Clinical Benefit Rate (CBR).
Secondary end points are evaluation of safety and tolerability, progression-free survival, time to treatment failure, duration of response and overall survival. Incorporated translational endpoints include examination of molecular tumor adaptation in tissue and blood. Given the role of PI3K in cellular glucose metabolism, an additional exploratory objective is to determine if quantitive reduction in metabolic signal on Positron Emission Tomography-Computed Tomography (PET-CT) is predictive of benefit from therapy.
Statistical methods
To establish the MTD, we use a modified 3+3 design where 3 additional patients will be accrued even if the first 3 patients accrued experience no dose limiting toxicities (DLT) in sequential cohorts for a planned 12 patients. To determine the CBR, a one sample exact binomial test with a one sided significance level of 5%, 19 evaluable patients will provide >80% power to detect a difference between the null hypothesis proportion of 30% for CBR versus the alternative hypothesis proportion of 65%.
Present accrual and target accrual
There are 9 patients recruited so far to the phase Ib part of this study. Target accrual is 12 and for phase II is 19 patients.
Contact information for people with a specific interest in the trial
Prof Bryan Hennessy, Beaumont Hospital, Dublin Ireland
Funded by Bayer
Citation Format: Keegan NM, Walshe J, Gullo G, Kennedy J, Bulger K, Kelly CM, Crown J, Toomey S, Egan K, Kerr J, Given M, Hernando A, Teiserskiene A, Grogan L, Breathnach O, Morris PG, Keane M, Hennessy BT. A phase Ib/II trial of coPANlisib in combination with tratuzumab in pretreated recurrent or metastatic HER2-positive breast cancer “PantHER” [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr OT3-06-05.
Collapse
Affiliation(s)
- NM Keegan
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| | - J Walshe
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| | - G Gullo
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| | - J Kennedy
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| | - K Bulger
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| | - CM Kelly
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| | - J Crown
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| | - S Toomey
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| | - K Egan
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| | - J Kerr
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| | - M Given
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| | - A Hernando
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| | - A Teiserskiene
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| | - L Grogan
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| | - O Breathnach
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| | - PG Morris
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| | - M Keane
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| | - BT Hennessy
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| |
Collapse
|
17
|
Kelly C, Feighery R, McCaffrey J, Higgins M, Smith M, O'Reilly S, Murphy C, Horgan A, Walshe J, McDermott R, O'Donnell D, Morris P, Keane M, Martin M, Duffy K, Mihai A, Armstrong J, Mulroe E, Murphy V, Kelly C. Do oncology patients understand clinical trials? A nationwide study by Cancer Trials Ireland. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx440.068] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
18
|
Crown J, Walshe J, Fennelly D, Long JC, Cairney S, McDonnell D, Ballot J, Wildes D, Sills E, Gullo G. Incidence of permanent alopecia following adjuvant chemotherapy in women with early stage breast cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx362.056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
19
|
Gullo G, Walsh N, Fennelly D, Tryphonopoulos D, Walshe J, O'Mahony K, Silva N, Hammond L, Ballot J, Quinn C, Buckley C, Crown J. Timing of initiation of trastuzumab (T) and long-term outcome of patients (pts) with early-stage (ES) HER2-positive (HER2+) breast cancer (BrCa): Impact of neo-adjuvant (NAdj) versus adjuvant (Adj) strategy. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx362.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
20
|
Kelly C, Feighery R, McCaffrey J, Higgins M, Smith M, O'Reilly S, Horgan A, Walshe J, McDermott R, O'Donnell D, Morris P, Keane M, Martin M, Murphy C, Duffy K, Mihai A, Armstrong J, Mulroe E, Murphy V, Kelly C. Decisions and supports around clinical trial participation: A national study by Cancer Trials Ireland. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx385.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
21
|
Picardo S, Sui J, Greally M, Woulfe B, Prior L, Corrigan L, O'Leary C, Mullally W, Walshe J, McCaffrey J, O'Connor M, O'Mahony D, Coate L, Gupta R, O'Reilly S. Oncotype DX score, menopausal status and body mass index. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx362.043] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
22
|
Millen S, Walshe J. A pooled analysis of observational studies evaluating the impact of multi-gene assay testing on adjuvant treatment decisions in “real-world” clinical practice for women with early breast cancer. Breast 2017. [DOI: 10.1016/s0960-9776(17)30319-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
23
|
Gennari A, Sun Z, Hasler-Strub U, Colleoni M, Kennedy J, von Moos R, Cortes J, Vidal M, Hennessy B, Walshe J, Amillano Parraga K, Morales Murrillo S, Pagani O, Barbeaux A, Borstnar S, Rabaglio M, Maibach R, Regan MM, Jerusalem G. Abstract P5-15-05: Randomized phase II study evaluating different schedules of nab-paclitaxel in metastatic breast cancer (MBC): Results of the SNAP study. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p5-15-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Longer chemotherapy (CT) duration is associated with a significant improvement in progression-free survival (PFS) and a moderate, but significant improvement in overall survival (OS) in MBC patients (pts). Prolonged CT administration, however, must be weighed against the side effects of continuous CT delivery. The SNAP trial was designed to improve the tolerability of prolonged CT by studying alternative treatment schedules.
Methods
The SNAP trial enrolled 258 women from April 2013 to Aug 2015. Eligibility criteria included HER2- MBC, no prior CT for advanced disease, measurable and/or non-measurable disease.
All eligible pts were randomized to one of three arms. Pts received the same induction chemotherapy consisting of 3 cycles of nab-Paclitaxel given days 1,8,15 Q28, followed by one of the three maintenance therapy schedules. Originally, the dose of the induction chemotherapy was 150 mg/m2, but this was reduced to 125 mg/m2 following the first safety review of 48 treated pts. The three schedules of nab-Paclitaxel used as maintenance therapy were (Arm A) nab-Paclitaxel 150 mg/m2 d 1,15 Q28; (Arm B) nab-Paclitaxel 100 mg/m2 d 1,8,15 Q28; (Arm C) nab-Paclitaxel 75 mg/m2 d 1,8,15,22 Q28.
The primary objective is to evaluate the efficacy of three nab-Paclitaxel regimens as measured by progression-free survival (PFS), using the historical reference of PFS (based on AVADO study) of docetaxel for first-line treatment of metastatic breast cancer. Each of the three regimens is compared to the historic 7-month median PFS to determine whether any of the three regimens are worthy of further investigation. Secondary endpoints include tolerability, feasibility, response rate, OS and QoL.
Results
Two-hundred-fifty-eight pts have been randomised and 255 are available for primary endpoint evaluation. At 18.2 months' median follow-up, 182 PFS events and 85 deaths have been observed. Median PFS was 7.9 months (90%CI 6.8-8.4) in Arm A, 9.0 months (90%CI 8.1-10.9) in Arm B and 8.5 (90%CI 6.7-9.5) in Arm C. PFS in Arm B was significantly longer than the historic PFS of first-line docetaxel (one-sided log-rank p=0.03).
As expected, neurotoxicity was the most frequent adverse event. In the induction phase, grade≥2 sensory neuropathy was reported in 14.8% of pts at the starting dose of 150 mg/m2 and 7.5% at the starting dose of 125 mg/m2; grade≥3 sensory neuropathy occurred in 2.5% and 0% of the pts, respectively. In the maintenance phase, grade≥2 sensory neuropathy was reported in 37.9% of pts in Arm A, 36.1% in Arm B and 31.2% in Arm C; grade≥3 sensory neuropathy occurred in 9.1%, 5.6% and 6.6% of the pts, respectively.
199 pts started the maintenance phase. The median number of maintenance cycles was 3, 4, and 5, respectively. Stopping maintenance for reasons other than objective progression occurred in 41%, 58%, and 53%, respectively.
Conclusion
The SNAP trial indicates that alternative maintenance chemotherapy schedules with reduced doses after a short term induction phase at conventional doses are feasible and significantly more active than the historical PFS of docetaxel in the first line treatment of advanced breast cancer.
Citation Format: Gennari A, Sun Z, Hasler-Strub U, Colleoni M, Kennedy J, von Moos R, Cortes J, Vidal M, Hennessy B, Walshe J, Amillano Parraga K, Morales Murrillo S, Pagani O, Barbeaux A, Borstnar S, Rabaglio M, Maibach R, Regan MM, Jerusalem G. Randomized phase II study evaluating different schedules of nab-paclitaxel in metastatic breast cancer (MBC): Results of the SNAP study [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-15-05.
Collapse
Affiliation(s)
- A Gennari
- International Breast Cancer Study Group (Bern, Switzerland), Cancer Trials Ireland (Dublin, Ireland), and SOLTI (Barcelona, Spain)
| | - Z Sun
- International Breast Cancer Study Group (Bern, Switzerland), Cancer Trials Ireland (Dublin, Ireland), and SOLTI (Barcelona, Spain)
| | - U Hasler-Strub
- International Breast Cancer Study Group (Bern, Switzerland), Cancer Trials Ireland (Dublin, Ireland), and SOLTI (Barcelona, Spain)
| | - M Colleoni
- International Breast Cancer Study Group (Bern, Switzerland), Cancer Trials Ireland (Dublin, Ireland), and SOLTI (Barcelona, Spain)
| | - J Kennedy
- International Breast Cancer Study Group (Bern, Switzerland), Cancer Trials Ireland (Dublin, Ireland), and SOLTI (Barcelona, Spain)
| | - R von Moos
- International Breast Cancer Study Group (Bern, Switzerland), Cancer Trials Ireland (Dublin, Ireland), and SOLTI (Barcelona, Spain)
| | - J Cortes
- International Breast Cancer Study Group (Bern, Switzerland), Cancer Trials Ireland (Dublin, Ireland), and SOLTI (Barcelona, Spain)
| | - M Vidal
- International Breast Cancer Study Group (Bern, Switzerland), Cancer Trials Ireland (Dublin, Ireland), and SOLTI (Barcelona, Spain)
| | - B Hennessy
- International Breast Cancer Study Group (Bern, Switzerland), Cancer Trials Ireland (Dublin, Ireland), and SOLTI (Barcelona, Spain)
| | - J Walshe
- International Breast Cancer Study Group (Bern, Switzerland), Cancer Trials Ireland (Dublin, Ireland), and SOLTI (Barcelona, Spain)
| | - K Amillano Parraga
- International Breast Cancer Study Group (Bern, Switzerland), Cancer Trials Ireland (Dublin, Ireland), and SOLTI (Barcelona, Spain)
| | - S Morales Murrillo
- International Breast Cancer Study Group (Bern, Switzerland), Cancer Trials Ireland (Dublin, Ireland), and SOLTI (Barcelona, Spain)
| | - O Pagani
- International Breast Cancer Study Group (Bern, Switzerland), Cancer Trials Ireland (Dublin, Ireland), and SOLTI (Barcelona, Spain)
| | - A Barbeaux
- International Breast Cancer Study Group (Bern, Switzerland), Cancer Trials Ireland (Dublin, Ireland), and SOLTI (Barcelona, Spain)
| | - S Borstnar
- International Breast Cancer Study Group (Bern, Switzerland), Cancer Trials Ireland (Dublin, Ireland), and SOLTI (Barcelona, Spain)
| | - M Rabaglio
- International Breast Cancer Study Group (Bern, Switzerland), Cancer Trials Ireland (Dublin, Ireland), and SOLTI (Barcelona, Spain)
| | - R Maibach
- International Breast Cancer Study Group (Bern, Switzerland), Cancer Trials Ireland (Dublin, Ireland), and SOLTI (Barcelona, Spain)
| | - MM Regan
- International Breast Cancer Study Group (Bern, Switzerland), Cancer Trials Ireland (Dublin, Ireland), and SOLTI (Barcelona, Spain)
| | - G Jerusalem
- International Breast Cancer Study Group (Bern, Switzerland), Cancer Trials Ireland (Dublin, Ireland), and SOLTI (Barcelona, Spain)
| |
Collapse
|
24
|
Gullo G, Walsh N, Zacchia A, Hammond L, Fennelly D, Walshe J, O’Mahony K, Maltese M, Crown J. Clinical factors associated with overall survival (OS) for patients with HER2-positive (HER2+) metastatic breast cancer (MBC) treated with HER2-targeting systemic therapy (HER2Tx). Eur J Cancer 2017. [DOI: 10.1016/s0959-8049(17)30224-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
25
|
Hinde D, Dasgupta M, Jeung D, Mohanto G, Prasad E, Simenel C, Walshe J, Wahkle A, Williams E, Carter I, Cook K, Kalkal S, Rafferty D, Rietz RD, Simpson E, David H, Düllmann C, Khuyagbaatar J. Quasifission in heavy and superheavy element formation reactions. EPJ Web Conf 2016. [DOI: 10.1051/epjconf/201613104004] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
26
|
Gullo G, Bose R, Walsh N, Maltese M, Fennelly D, Walshe J, Ballot J, Crown J. Delayed initiation of HER2-targeted therapy (HER2Tx) is associated with a higher risk of relapse for early stage (ES) HER2-positive (HER2+) breast cancer (BrCa). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw364.64] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
27
|
Rafee S, McHugh D, Greally M, Ayodele O, Keegan N, Lim M, Hassan A, O'Mahony D, Hennessy B, Kelly C, Kennedy J, Walshe J, O'Connor M, Leonard G, Murphy V, Livingstone V, Corrigan M, O'Reilly S. Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as predictive biomarkers of pathologic complete response (pCR) in neoadjuvant breast cancer: an Irish Clinical Oncology Group study (ICORG 16-20). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw392.20] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
28
|
Gullo G, Quinn C, Zacchia A, Fennelly D, Defrein A, Ballot J, Zanoni D, Walshe J, Maltese M, McDermott E, Crown J. Abstract P4-14-15: Pre-treatment stromal tumour-infiltrating lymphocytes (S-TILs) are correlated with complete response (CR) to chemotherapy (Chemo) plus trastuzumab (T) in HER2-positive (H+) metastatic breast cancer (MBC). Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p4-14-15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background. We have previously reported that ChemoT produces durable (>5 years) CR in a minority of pts with H+MBC, prompting a search for predictive markers. Extensive lymphocytic infiltration of cancers is correlated with high levels of immune gene signatures. International consensus guidelines on TILs define "lymphocyte-predominant BC" at a threshold of S-TILs of 50-60% versus tumour cells. High levels of S-TILs has been correlated with improved outcome in HER2+ early stage BC pts treated with ChemoT. We investigated the degree of S-TIL infiltration in metastatic biopsies from pts with HER2+MBC prior to ChemoT, and attempted to determine whether S-TILs predicted CR in HER2+MBC.
Methods. We searched a database of all pts with HER2+ MBC treated at our institution with anti-HER2 therapy over 15yrs to identify pts who achieved CR according to RECIST 1.0 criteria, which lasted for at least 6 months. We matched them with an equal number of pts from the database who were treated during the same period, but who had progressive (POD) or stable disease (SD) as best response to T. Pts must have at least one pre-treatment tumour sample available for S-TILs assessment, and adequate clinical and follow-up information. S-TILs (mononuclear cells including lymphocytes and plasma cells) contained within the boundaries of invasive tumour were identified on a representative haematoxylin and eosin stained slide and scored as a percentage of the stromal area alone, according to the International TILs Working Group 2014 methodology [Salgado R, 2015]. S-TILs were assessed specifically for this study by a senior pathologist who scored the samples and who was blinded to pts response and clinical details.
Results. Out of 246 MBC pts registered in the HER2+ database we identified 31 CR pts with at least one available pre-treatment metastatic sample. A cohort of 31 matching POD-SD pts was randomly obtained from the same database. In 8 cases (7 CR / 1 POD-SD) S-TILs could not be assessed due to inadequate material, or for other technical reasons. The final study sample is 54 pts (24 CR / 30 POD-SD). Pts characteristics are as follows: median age (range): CR 55 (29-78) / POD-SD 56 (26-89), hormone receptor (HR) pos: CR 12 (50%) / POD-SD 18 (60%), De Novo MBC at diagnosis: CR 13 (54%) / POD-SD 8 (27%) [p<0.05]. All pts received chemotherapy with T (+ lapatinib in 3 pts as part of a clinical trial), and continued on T until POD. Pre-treatment S-TILs >50% were statistically significantly more frequent in CR (50% of pts) than POD/SD (20%) [chi-square p=0.02]. No statistically significant difference in the HR status was observed between the two groups (CR vs POD-SD) or between the high and low S-TILs pts.
Conclusions. S-TILs >50% in the pre-treatment tumour biopsy of HER2+MBC were significantly correlated with subsequent CR to ChemoT, supporting the hypothesis that the immunological effects of T may play a role in determining response. Speculatively, S-TILs might identify pts with a higher likelihood of benefit from T. Further study of the potential role of S-TILs as predictors of T benefit are required.
Citation Format: Gullo G, Quinn C, Zacchia A, Fennelly D, Defrein A, Ballot J, Zanoni D, Walshe J, Maltese M, McDermott E, Crown J. Pre-treatment stromal tumour-infiltrating lymphocytes (S-TILs) are correlated with complete response (CR) to chemotherapy (Chemo) plus trastuzumab (T) in HER2-positive (H+) metastatic breast cancer (MBC). [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-14-15.
Collapse
Affiliation(s)
- G Gullo
- St Vincent's University Hospital, Dublin, Ireland
| | - C Quinn
- St Vincent's University Hospital, Dublin, Ireland
| | - A Zacchia
- St Vincent's University Hospital, Dublin, Ireland
| | - D Fennelly
- St Vincent's University Hospital, Dublin, Ireland
| | - A Defrein
- St Vincent's University Hospital, Dublin, Ireland
| | - J Ballot
- St Vincent's University Hospital, Dublin, Ireland
| | - D Zanoni
- St Vincent's University Hospital, Dublin, Ireland
| | - J Walshe
- St Vincent's University Hospital, Dublin, Ireland
| | - M Maltese
- St Vincent's University Hospital, Dublin, Ireland
| | - E McDermott
- St Vincent's University Hospital, Dublin, Ireland
| | - J Crown
- St Vincent's University Hospital, Dublin, Ireland
| |
Collapse
|
29
|
Greally M, Kielty J, Das G, Malouf C, O'Riordan L, Coleman N, Quinn C, McDermott E, Gullo G, Kelly C, Crown J, Prichard R, Walshe J. Abstract P1-07-09: Retrospective cohort study of patients (pts) diagnosed with breast cancer (BC) <40 yrs: 2000 to 2015⟨. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p1-07-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Young women (<40 yrs) with breast cancer (YWBC) account for 7-12% of BC diagnoses. BC is the leading cause of cancer death in this group (G). Age-specific data on outcome and appropriate treatment (Rx) are lacking. YWBC appear to have more biologically aggressive subtypes and a higher risk of relapse and death. We studied the clinico-pathological (ClinPath) characteristics in YWBC, examining how outcomes/Rx have evolved.
Methods
YWBC were identified from pathology databases at 2 tertiary centers. Pts were divided into 2 cohorts: BC diagnoses from 2000-2007 (G1) and 2008-2015 (G2). ClinPath and Rx data were retrieved from clinical, radiology and histology databases. Statistical analysis was performed using SPSS.
Results
We identified 347 pts. Tumor features are shown in Table I. Median age is 36 (23-39). By histology, 90.8% (n=315) had invasive ductal carcinoma, 53.1% (n=181) had Grade III BC and 56.3% (n=171) had lymphovascular invasion. Pregnancy-associated BC occurred in 10.7% (n=34). Mastectomy (MX) was performed in 53% (n=176) and axillary lymph node clearance (ALNC) in 63.8% (n=192 [G1: 84.3% vs. G2: 48.6%, p<0.001]).
Table 1Tumor features Group 1 (n=149)Group 2 (n=198)Total (n=347)p-valueMedian tumor size (mm) 252222.5p=0.115Node positivity 88 (60.3%)100(51.5%)188 (55.3%)p=0.109Median node count 4 (1-44)1 (1-30)2 (1-44)p<0.001StageI 99(29%) II 148 (43.3%) III 70 (20.5%) IV 23(7.3%) Biomarker status*ER+/HER2-76 (53.1%)120 (60.6%)196 (56%)p=0.086 HER2+41 (28.7%)45 (22.8%)86 (27%)p=0.031 Triple negative (TN)26 (18.2%)33 (16.8%)59 (17%)p=0.291* Missing data n=6
Rx characteristics are shown in Table 2. 85 pts received neo-adjuvant therapy (NAT); 48.3% (n=41) ER+/HER2-, 27% (n=23) HER2+ and 24.7% (n=21) TNBC. Pts receiving NAT in G2 trended towards improved pCR rate (G2: 24.6% vs G1: 8.3%, p=0.057). Endocrine Rx alone was received by 9.8% (n=22); 13.6% (n=18) in G2 vs 4.3% (n=4) in G1. OncotypeDx(ODx) was used in 23 pts (14.9%) (median score 17), 1 had a DR (ODx Score = 18).
Table 2Tx characteristics n=347 Chemotherapy Total300(86.4%) NAT85 (28.3%)Pathological Complete Response (pCR)* pCR (n=16, 19.8%)No pCR (n=65, 80.2%) ER+/HER2-18.8%(n=3)53.9% (n=35) HER2+/ER+18.8%(n=3)13.8% (n=9) HER2+/ER-31.2% (n=5)9.2% (n=6) TNBC31.2%(n=5)23.1%(n=15)Local relapse 1 (6.2%)1(1.5%)Distant relapse (DR) 022(33.8%)*Data incomplete n=4
DR occurred in 50 pts (16%), including 13 (20.3%) HER2+ pts. Of note, 92.3% (n=12) of these were in G1. Relapse rates (RR) in TN and ER+/HER- pts were 19.6% (n=11) and 13.7% (n=26) respectively. There was a higher RR in G1 (34.8% vs 11.4%, p<0.001). Overall survival in pts with stage IV dx was 32 mos in G1 and 48 mos in G2.
Conclusion
In line with existing data, locally advanced dx is more prevalent in YWBC. MX and ALNC rates were high and most received multimodal Rx. The extent of axillary surgery declined. Pts in G2 had lower volume BC at diagnosis suggesting increasing awareness. TN and HER2+ subtypes accounted for a slightly higher proportion of BC cases. Pts with PCR had better outcomes. Only 16% relapsed with metastatic dx. The impact of HER2 Rx is highlighted by reduced RR in HER2+ G2 pts. Outcomes were unchanged in pts with ER+/HER2- and TNBC. These remain a priority for future research.
Citation Format: Greally M, Kielty J, Das G, Malouf C, O'Riordan L, Coleman N, Quinn C, McDermott E, Gullo G, Kelly C, Crown J, Prichard R, Walshe J. Retrospective cohort study of patients (pts) diagnosed with breast cancer (BC) <40 yrs: 2000 to 2015⟨. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P1-07-09.
Collapse
Affiliation(s)
- M Greally
- St. Vincent's University & Private Hospitals, Dublin, Ireland; Mater Misercordiae University Hospital, Dublin, Ireland
| | - J Kielty
- St. Vincent's University & Private Hospitals, Dublin, Ireland; Mater Misercordiae University Hospital, Dublin, Ireland
| | - G Das
- St. Vincent's University & Private Hospitals, Dublin, Ireland; Mater Misercordiae University Hospital, Dublin, Ireland
| | - C Malouf
- St. Vincent's University & Private Hospitals, Dublin, Ireland; Mater Misercordiae University Hospital, Dublin, Ireland
| | - L O'Riordan
- St. Vincent's University & Private Hospitals, Dublin, Ireland; Mater Misercordiae University Hospital, Dublin, Ireland
| | - N Coleman
- St. Vincent's University & Private Hospitals, Dublin, Ireland; Mater Misercordiae University Hospital, Dublin, Ireland
| | - C Quinn
- St. Vincent's University & Private Hospitals, Dublin, Ireland; Mater Misercordiae University Hospital, Dublin, Ireland
| | - E McDermott
- St. Vincent's University & Private Hospitals, Dublin, Ireland; Mater Misercordiae University Hospital, Dublin, Ireland
| | - G Gullo
- St. Vincent's University & Private Hospitals, Dublin, Ireland; Mater Misercordiae University Hospital, Dublin, Ireland
| | - C Kelly
- St. Vincent's University & Private Hospitals, Dublin, Ireland; Mater Misercordiae University Hospital, Dublin, Ireland
| | - J Crown
- St. Vincent's University & Private Hospitals, Dublin, Ireland; Mater Misercordiae University Hospital, Dublin, Ireland
| | - R Prichard
- St. Vincent's University & Private Hospitals, Dublin, Ireland; Mater Misercordiae University Hospital, Dublin, Ireland
| | - J Walshe
- St. Vincent's University & Private Hospitals, Dublin, Ireland; Mater Misercordiae University Hospital, Dublin, Ireland
| |
Collapse
|
30
|
Gullo G, Kennedy J, Breathnach O, McCaffrey J, Keane M, Martin M, Gupta R, Leonard G, Calvert P, Donnellan P, Walshe J, Mc Dermott E, Cairney S, Bose R, Scott K, Hernando A, Parker I, Tryfonopoulos D, Moulton B, Crown J. 1964 Pilot study of bevacizumab (Bev) in combination with docetaxel (T) and cyclophosphamide (C) as adjuvant treatment (AdjRx) for patients (pts) with early stage (ES) HER-2 normal breast cancer (BrCa) ICORG 08-10. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30912-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
31
|
Marques MD, Critchley CR, Walshe J. Attitudes to genetically modified food over time: How trust in organizations and the media cycle predict support. Public Underst Sci 2015; 24:601-618. [PMID: 25063421 DOI: 10.1177/0963662514542372] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
This research examined public opinion toward genetically modified plants and animals for food, and how trust in organizations and media coverage explained attitudes toward these organisms. Nationally representative samples (N=8821) over 10 years showed Australians were less positive toward genetically modified animals compared to genetically modified plants for food, especially in years where media coverage was high. Structural equation modeling found that positive attitudes toward different genetically modified organisms for food were significantly associated with higher trust in scientists and regulators (e.g. governments), and with lower trust in watchdogs (e.g. environmental movement). Public trust in scientists and watchdogs was a stronger predictor of attitudes toward the use of genetically modified plants for food than animals, but only when media coverage was low. Results are discussed regarding the moral acceptability of genetically modified organisms for food, the media's role in shaping public opinion, and the role public trust in organizations has on attitudes toward genetically modified organisms.
Collapse
|
32
|
Gullo G, De Giorgi A, O'Donovan N, Fennelly D, Walshe J, Ballot J, McDermott E, Evoy D, Jordan E, Crown J. Long-Term Outcome of Patients (Pts) with Her2-Positive (Her2+) Metastatic Breast Cancer (Mbc) Who Achieved a Complete Response (Cr) After Antiher2 Therapy (Her2Tx). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu329.25] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
33
|
John P, Modamio V, Valiente-Dobón J, Mengoni D, Gottardo A, Bazzacco D, Lunardi S, Alexander T, Angelis GD, Ashwood N, Barr M, Bizzeti P, Bizzeti-Sona A, Bottoni S, Bowry M, Bracco A, Browne F, Bunce M, Gadea A, Camera F, Corradi L, Crespi F, Farnea E, Fioretto E, Kokalova T, Korten W, Kuşoğlu A, Lenzi S, Leoni S, Michelagnoli C, Mijatović T, Montagnoli G, Montanari D, Napoli D, Podolyák Z, Pollarolo G, Recchia F, Roberts O, Şahin E, Salsac MD, Scarlassara F, Stefanini A, Szilner S, Ur C, Walshe J, Wheldon C. Study of shape transition in the neutron-rich Os isotopes. EPJ Web of Conferences 2014. [DOI: 10.1051/epjconf/20146602057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
34
|
Crown J, Coate L, Keane M, Kennedy J, O'Reilly S, Kelly C, O'Connor M, Martin M, Duffy K, Murphy C, Walshe J, O'Shea T, Moulton B, Egan K, O'Donovan N, Gullo G, Geraghty K, Hennessy B. Abstract P4-12-25: Randomized phase II study of pre-operative docetaxel, carboplatin with trastuzumab (TCH) and/or/lapatinib (L) in HER-2 positive (H+) breast cancer patients (BC pts). ICORG 10-05. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p4-12-25] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The addition of trastuzumab (H) to pre-operative chemotherapy in H+BC increases the rate of pathological complete remission (pCR). H causes cardiac toxicity, especially when given with anthracyclines (Anth). TCH is a widely used adjuvant regimen with decreased cardiac toxiciy. We reported that TCH produces pCR in 40% of non-randomised pts with H+BC. Lapatinib is an alternative HER2 antagonist, which produces responses following trastuzumab failure, and which has been reported to augment H activity in combination. We studied the non-Anth regimens TCH v TCL v TCHL in pts with H+BC. The primary objective of this study was pCR. Secondary endpoints were toxicity and translational.
Methods: Eligibility criteria included: primary BC, HER-2 +, node + disease (histologically or cytologically confirmed) or node-negative with >T1, normal left ventricle ejection fraction, no active/uncontrolled cardiovascular disease, normal organ and marrow function. Treatment consisted of 6 cycles of D (75mg/m2) + C (AUC 6) q3 weekly and H (8 mg/kg on cycle 1 day 1 and 6 mg/kg q3weekly thereafter for one year) ± L (1000mg OD) for up to 1 week before surgery. A sample size of 36 evaluable pts is required to detect an absolute 25% difference in the pCR rate between the hypothesised 65% pCR rate vs the historical-control pCR rate of 40%.
Results: Following presentation of NCIC MA31 we decided to suspend accrual on our TCL arm.78 female pts were accrued to TCH/TCHL in 11 ICORG sites between 12/2010- 06/2013. Of 40 patients accrued to TCHL, only 18 pts completed 6 cycles. 17pts came off study early due to toxicity, 3 pts after cycle 3, 2 pts after cycle 2, 12pts after cycle 1. (1 patient was also registered but never started). Of 38 pts accrued to the TCH arm,33 pts completed 6 cycles,2 pts completed 5 cycles and 2 pts w/d after cycle 1. 3 TCHL & 1 TCH pt still remain on Rx. 2 pts have not yet had surgery. 52 SAEs occurred on study, 49 involving hospital admission, & 3 of medical significance. The most frequent SAEs were diarrhoea (10), febrile neutropenia (4), nausea (4), neutropenic sepsis (3), dehydration (2), wound infection (2), vomiting (2) neutropenia (2) decreased haemoglobin (2), GI perforation (1). There was 1 fatality on the TCH arm due to Neutropenic sepsis and typhlitis. One TCHL pt suffered GI perforation at cycle 1. pCR rates were 48% (16/33) for the TCH arm and 44% (7/16) for the TCHL arm. Translational studies are underway.
Conclusions: TCH containing treatment produces a high rate of pCR. TCHL will not produce a statistically higher rate of pCR in this sample. The addition of lapatinib to TCH results in substantial GI toxicity. TCHL appears to be less tolerable than other active chemotherapy +H+L regimens such as that used in Neo-ALLTO. ICORG is currently leading an international study of paclitaxel+H +/- L in metastatic BC.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P4-12-25.
Collapse
Affiliation(s)
- J Crown
- All-Ireland Co-Operative Oncology Research Group, Dublin 2, Ireland
| | - L Coate
- All-Ireland Co-Operative Oncology Research Group, Dublin 2, Ireland
| | - M Keane
- All-Ireland Co-Operative Oncology Research Group, Dublin 2, Ireland
| | - J Kennedy
- All-Ireland Co-Operative Oncology Research Group, Dublin 2, Ireland
| | - S O'Reilly
- All-Ireland Co-Operative Oncology Research Group, Dublin 2, Ireland
| | - C Kelly
- All-Ireland Co-Operative Oncology Research Group, Dublin 2, Ireland
| | - M O'Connor
- All-Ireland Co-Operative Oncology Research Group, Dublin 2, Ireland
| | - M Martin
- All-Ireland Co-Operative Oncology Research Group, Dublin 2, Ireland
| | - K Duffy
- All-Ireland Co-Operative Oncology Research Group, Dublin 2, Ireland
| | - C Murphy
- All-Ireland Co-Operative Oncology Research Group, Dublin 2, Ireland
| | - J Walshe
- All-Ireland Co-Operative Oncology Research Group, Dublin 2, Ireland
| | - T O'Shea
- All-Ireland Co-Operative Oncology Research Group, Dublin 2, Ireland
| | - B Moulton
- All-Ireland Co-Operative Oncology Research Group, Dublin 2, Ireland
| | - K Egan
- All-Ireland Co-Operative Oncology Research Group, Dublin 2, Ireland
| | - N O'Donovan
- All-Ireland Co-Operative Oncology Research Group, Dublin 2, Ireland
| | - G Gullo
- All-Ireland Co-Operative Oncology Research Group, Dublin 2, Ireland
| | - K Geraghty
- All-Ireland Co-Operative Oncology Research Group, Dublin 2, Ireland
| | - B Hennessy
- All-Ireland Co-Operative Oncology Research Group, Dublin 2, Ireland
| |
Collapse
|
35
|
Marie-Lucile F, Laure-Helene N, Yosr C, Anne M, Fadi F, Levi C, Levi C, Meas-Yedid V, Daniliuc C, Karras A, Olivo-Marin JC, Mouthon L, Guiard E, Roland M, Guillevin L, Jacquot C, Nochy D, Thervet E, Chen Q, Skerka C, Uzonyi B, Lindner S, Licht C, Hoppe B, Riedl M, Kirschfink M, Habbich S, Wolf G, Strain L, Goodship TH, Zipfel PF, Kfoury H, Alsuwaida A, Alsaad K, Alhejaili F, Alghonaim M, Alwakeel J, Husain S, Aloudah N, Besso L, Besso L, Tamagnone M, Daidola G, Burdese M, Repetto L, Pasquale G, Colla L, Biancone L, Stratta P, Segoloni GP, Bacalja J, Bauer Segvic AM, Bulimbasic S, Pacic A, Knotek M, Sabljar Matovinovic M, Galesic K, Galesic Ljubanovic D, Zakharova E, Stolyarevich E, Vorobjova O, Tamouza H, Chemouny JM, Flamant M, Raskova Kafkova L, Demion M, Laurent M, Walker F, Julian BA, Tissandie E, Tiwari MK, Novak J, Camara NO, Benhamou M, Vrtovsnik F, Monteiro RC, Moura IC, Samavat S, Ahmadpoor P, Torbati P, Ghaderi R, Poorrezagholi F, Samadian F, Nafar M, MII A, MII A, Shimizu A, Kaneko T, Yasuda F, Fukui M, Masuda Y, Iino Y, Katayama Y, Muller C, Markovic-Lipkovski J, Simic-Ogrizovic S, Naumovic R, Cirovic S, Mitrovic D, Muller G, Wozniak A, Janicka-Jedynska M, Zurawski J, Kaczmarek E, Zachwieja J, Khilji S, Khilji S, Dorman T, O'kelly P, Lampty L, Leung K, Shadivan A, Varghese C, Walshe J, Saito T, Kawano M, Saeki T, Mizushima I, Yamaguchi Y, Imai N, Nakashima H, Umehara H, Shvetsov M, Popova O, Chebotareva N, Ivanov A, Bobkova I, Cremasco D, Ceol M, Peruzzi L, Mazzucco G, Giuseppina M, Vezzoli G, Cristofaro R, D'angelo A, Anglani F, Del Prete D, Coppolino G, Comi N, Bolignano D, Piraina V, Talarico R, Colombo A, Lucisano G, Fuiano G, Bernich P, Lupo A, Of Renal Biopsies TR, Rastaldi MP, Jercan OC, Messa P, Alexandru D, Mogoanta L, Jercan OC, Shvetsov M, Ivanov A, Uribe Villegas V, Popova O. Renal histopathology. Nephrol Dial Transplant 2012. [DOI: 10.1093/ndt/gfs242] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
36
|
Finn RS, Crown JP, Boer K, Lang I, Parikh RJ, Patel R, Schmidt M, Hagenstad C, Lim H, Pinter T, Amadori D, Chan D, Dichmann RA, Walshe J, Breazna A, Kim ST, Randolph S, Slamon DJ. P1-17-05: Preliminary Results of a Randomized Phase 2 Study of PD 0332991, a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor, in Combination with Letrozole for First-Line Treatment of Patients (pts) with Post-Menopausal, ER+, HER2−Negative (HER2–) Advanced Breast Cancer. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p1-17-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: PD 0332991 is an orally bioavailable selective inhibitor of CDK 4/6 and prevents cellular DNA synthesis by prohibiting progression of the cell cycle from G1 into the S phase. Preclinical evaluations suggest that reduction in CDKN2A (p16) expression and cyclin D1 (CCND1) overexpression confer susceptibility to PD 0332991 (Finn 2009). In addition, PD 0332991 was synergistic in combination with tamoxifen in vitro in ER+ human breast cancer cell lines. Based on these observations, a phase 1/2 study in combination with letrozole as first-line therapy for advanced ER+ post-menopausal breast cancer was initiated. The phase 1 part of the study (completed) determined the recommended phase 2 dose to be PD 0332991 125 mg QD on Schedule 3/1 (3 weeks on treatment followed by 1-week off treatment) in combination with letrozole 2.5 mg QD. The combination was generally well tolerated and encouraging antitumor activity was observed. We present preliminary data from the randomized Phase 2 portion comparing letrozole alone to letrozole plus PD 0332991.
Methods: The Phase 2 portion of the study is designed as a two-part study; we present data from Part 1. In both parts, eligible patients are randomized 1:1 to letrozole 2.5 mg QD alone (control) or PD 0332991 125 mg QD on schedule 3/1 and letrozole 2.5 mg QD (treatment, tx). Part 1enrolled post-menopausal women with ER+, HER2− cancer using only ER+, HER2−as a selection criteria. Part 2 is now enrolling post-menopausal women with ER+, HER2− breast cancer with CCND1 amplification and/or loss of p16 by FISH (target N=150). The primary endpoint is progression-free survival (PFS); secondary endpoints include overall survival, response rate, safety, and correlative studies. Pts are stratified for disease site and length from prior adjuvant therapy. Pts continue assigned study treatment until disease progression, unacceptable toxicity, or consent withdrawal and are followed every 2 months to assess disease status. Tumor tissue was required for participation.
Results: 66 patients have been randomized in Part 1. At the time of data cut-off (April 2011) median duration of treatment is 20 (range 4–64) wks for control and 27 (2-59) wks for tx. Dose reductions occurred in 9 pts on the tx arm and none on the control arm. There are no complete responses. The number of partial responses for pts with measurable disease are similar between arms (4/22 control vs 5/24 in tx). The number of pts with stable disease> 24 weeks was higher in the tx arm (5 vs 8). The number of pts with best response of progressive disease is lower in the treatment arm (2 vs 6). PFS data are immature. Twelve pts remain on control vs. 21 on tx. As in the Phase I portion of the study, the most common treatment-related AEs were neutropenia and leucopenia without febrile neutropenia. Biomarker studies for CCND1 amplification, p16 loss, RB status, and Ki67 are ongoing.
Conclusion: The combination of PD 0332991 and letrozole is well tolerated as first-line treatment of ER+, HER2− post-menopausal breast cancer. Updated efficacy data and biomarker data will be presented.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P1-17-05.
Collapse
Affiliation(s)
- RS Finn
- 1University of California at Los Angeles, Los Angeles, CA; Irish Cooperative Oncology Research Group, Dublin, Ireland; Szent Margit Korhaz, Budapest, Hungary; National Institute of Oncology, Budapest, Hungary; Comprehensive Cancer Centers of Nevada, Henderson, NV; Comprehensive Blood and Cancer Center, Bakersfield, CA; University Hospital Mainz, Mainz, Germany; Suburban Hematology-Oncology Associates, Lawrenceville, GA; British Columbia Cancer Agency, Vancouver, BC, Canada; Petz Aladár Megyei Okato Korhaz, Gyor, Hungary; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy; Cancer Care Associates Medical Group, Redondo Beach, CA; Central Coast Medical Oncology Corporation, Santa Maria, CA; Pfizer Oncology, La Jolla, CA; Pfizer Oncology, New York, NY
| | - JP Crown
- 1University of California at Los Angeles, Los Angeles, CA; Irish Cooperative Oncology Research Group, Dublin, Ireland; Szent Margit Korhaz, Budapest, Hungary; National Institute of Oncology, Budapest, Hungary; Comprehensive Cancer Centers of Nevada, Henderson, NV; Comprehensive Blood and Cancer Center, Bakersfield, CA; University Hospital Mainz, Mainz, Germany; Suburban Hematology-Oncology Associates, Lawrenceville, GA; British Columbia Cancer Agency, Vancouver, BC, Canada; Petz Aladár Megyei Okato Korhaz, Gyor, Hungary; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy; Cancer Care Associates Medical Group, Redondo Beach, CA; Central Coast Medical Oncology Corporation, Santa Maria, CA; Pfizer Oncology, La Jolla, CA; Pfizer Oncology, New York, NY
| | - K Boer
- 1University of California at Los Angeles, Los Angeles, CA; Irish Cooperative Oncology Research Group, Dublin, Ireland; Szent Margit Korhaz, Budapest, Hungary; National Institute of Oncology, Budapest, Hungary; Comprehensive Cancer Centers of Nevada, Henderson, NV; Comprehensive Blood and Cancer Center, Bakersfield, CA; University Hospital Mainz, Mainz, Germany; Suburban Hematology-Oncology Associates, Lawrenceville, GA; British Columbia Cancer Agency, Vancouver, BC, Canada; Petz Aladár Megyei Okato Korhaz, Gyor, Hungary; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy; Cancer Care Associates Medical Group, Redondo Beach, CA; Central Coast Medical Oncology Corporation, Santa Maria, CA; Pfizer Oncology, La Jolla, CA; Pfizer Oncology, New York, NY
| | - I Lang
- 1University of California at Los Angeles, Los Angeles, CA; Irish Cooperative Oncology Research Group, Dublin, Ireland; Szent Margit Korhaz, Budapest, Hungary; National Institute of Oncology, Budapest, Hungary; Comprehensive Cancer Centers of Nevada, Henderson, NV; Comprehensive Blood and Cancer Center, Bakersfield, CA; University Hospital Mainz, Mainz, Germany; Suburban Hematology-Oncology Associates, Lawrenceville, GA; British Columbia Cancer Agency, Vancouver, BC, Canada; Petz Aladár Megyei Okato Korhaz, Gyor, Hungary; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy; Cancer Care Associates Medical Group, Redondo Beach, CA; Central Coast Medical Oncology Corporation, Santa Maria, CA; Pfizer Oncology, La Jolla, CA; Pfizer Oncology, New York, NY
| | - RJ Parikh
- 1University of California at Los Angeles, Los Angeles, CA; Irish Cooperative Oncology Research Group, Dublin, Ireland; Szent Margit Korhaz, Budapest, Hungary; National Institute of Oncology, Budapest, Hungary; Comprehensive Cancer Centers of Nevada, Henderson, NV; Comprehensive Blood and Cancer Center, Bakersfield, CA; University Hospital Mainz, Mainz, Germany; Suburban Hematology-Oncology Associates, Lawrenceville, GA; British Columbia Cancer Agency, Vancouver, BC, Canada; Petz Aladár Megyei Okato Korhaz, Gyor, Hungary; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy; Cancer Care Associates Medical Group, Redondo Beach, CA; Central Coast Medical Oncology Corporation, Santa Maria, CA; Pfizer Oncology, La Jolla, CA; Pfizer Oncology, New York, NY
| | - R Patel
- 1University of California at Los Angeles, Los Angeles, CA; Irish Cooperative Oncology Research Group, Dublin, Ireland; Szent Margit Korhaz, Budapest, Hungary; National Institute of Oncology, Budapest, Hungary; Comprehensive Cancer Centers of Nevada, Henderson, NV; Comprehensive Blood and Cancer Center, Bakersfield, CA; University Hospital Mainz, Mainz, Germany; Suburban Hematology-Oncology Associates, Lawrenceville, GA; British Columbia Cancer Agency, Vancouver, BC, Canada; Petz Aladár Megyei Okato Korhaz, Gyor, Hungary; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy; Cancer Care Associates Medical Group, Redondo Beach, CA; Central Coast Medical Oncology Corporation, Santa Maria, CA; Pfizer Oncology, La Jolla, CA; Pfizer Oncology, New York, NY
| | - M Schmidt
- 1University of California at Los Angeles, Los Angeles, CA; Irish Cooperative Oncology Research Group, Dublin, Ireland; Szent Margit Korhaz, Budapest, Hungary; National Institute of Oncology, Budapest, Hungary; Comprehensive Cancer Centers of Nevada, Henderson, NV; Comprehensive Blood and Cancer Center, Bakersfield, CA; University Hospital Mainz, Mainz, Germany; Suburban Hematology-Oncology Associates, Lawrenceville, GA; British Columbia Cancer Agency, Vancouver, BC, Canada; Petz Aladár Megyei Okato Korhaz, Gyor, Hungary; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy; Cancer Care Associates Medical Group, Redondo Beach, CA; Central Coast Medical Oncology Corporation, Santa Maria, CA; Pfizer Oncology, La Jolla, CA; Pfizer Oncology, New York, NY
| | - C Hagenstad
- 1University of California at Los Angeles, Los Angeles, CA; Irish Cooperative Oncology Research Group, Dublin, Ireland; Szent Margit Korhaz, Budapest, Hungary; National Institute of Oncology, Budapest, Hungary; Comprehensive Cancer Centers of Nevada, Henderson, NV; Comprehensive Blood and Cancer Center, Bakersfield, CA; University Hospital Mainz, Mainz, Germany; Suburban Hematology-Oncology Associates, Lawrenceville, GA; British Columbia Cancer Agency, Vancouver, BC, Canada; Petz Aladár Megyei Okato Korhaz, Gyor, Hungary; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy; Cancer Care Associates Medical Group, Redondo Beach, CA; Central Coast Medical Oncology Corporation, Santa Maria, CA; Pfizer Oncology, La Jolla, CA; Pfizer Oncology, New York, NY
| | - H Lim
- 1University of California at Los Angeles, Los Angeles, CA; Irish Cooperative Oncology Research Group, Dublin, Ireland; Szent Margit Korhaz, Budapest, Hungary; National Institute of Oncology, Budapest, Hungary; Comprehensive Cancer Centers of Nevada, Henderson, NV; Comprehensive Blood and Cancer Center, Bakersfield, CA; University Hospital Mainz, Mainz, Germany; Suburban Hematology-Oncology Associates, Lawrenceville, GA; British Columbia Cancer Agency, Vancouver, BC, Canada; Petz Aladár Megyei Okato Korhaz, Gyor, Hungary; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy; Cancer Care Associates Medical Group, Redondo Beach, CA; Central Coast Medical Oncology Corporation, Santa Maria, CA; Pfizer Oncology, La Jolla, CA; Pfizer Oncology, New York, NY
| | - T Pinter
- 1University of California at Los Angeles, Los Angeles, CA; Irish Cooperative Oncology Research Group, Dublin, Ireland; Szent Margit Korhaz, Budapest, Hungary; National Institute of Oncology, Budapest, Hungary; Comprehensive Cancer Centers of Nevada, Henderson, NV; Comprehensive Blood and Cancer Center, Bakersfield, CA; University Hospital Mainz, Mainz, Germany; Suburban Hematology-Oncology Associates, Lawrenceville, GA; British Columbia Cancer Agency, Vancouver, BC, Canada; Petz Aladár Megyei Okato Korhaz, Gyor, Hungary; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy; Cancer Care Associates Medical Group, Redondo Beach, CA; Central Coast Medical Oncology Corporation, Santa Maria, CA; Pfizer Oncology, La Jolla, CA; Pfizer Oncology, New York, NY
| | - D Amadori
- 1University of California at Los Angeles, Los Angeles, CA; Irish Cooperative Oncology Research Group, Dublin, Ireland; Szent Margit Korhaz, Budapest, Hungary; National Institute of Oncology, Budapest, Hungary; Comprehensive Cancer Centers of Nevada, Henderson, NV; Comprehensive Blood and Cancer Center, Bakersfield, CA; University Hospital Mainz, Mainz, Germany; Suburban Hematology-Oncology Associates, Lawrenceville, GA; British Columbia Cancer Agency, Vancouver, BC, Canada; Petz Aladár Megyei Okato Korhaz, Gyor, Hungary; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy; Cancer Care Associates Medical Group, Redondo Beach, CA; Central Coast Medical Oncology Corporation, Santa Maria, CA; Pfizer Oncology, La Jolla, CA; Pfizer Oncology, New York, NY
| | - D Chan
- 1University of California at Los Angeles, Los Angeles, CA; Irish Cooperative Oncology Research Group, Dublin, Ireland; Szent Margit Korhaz, Budapest, Hungary; National Institute of Oncology, Budapest, Hungary; Comprehensive Cancer Centers of Nevada, Henderson, NV; Comprehensive Blood and Cancer Center, Bakersfield, CA; University Hospital Mainz, Mainz, Germany; Suburban Hematology-Oncology Associates, Lawrenceville, GA; British Columbia Cancer Agency, Vancouver, BC, Canada; Petz Aladár Megyei Okato Korhaz, Gyor, Hungary; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy; Cancer Care Associates Medical Group, Redondo Beach, CA; Central Coast Medical Oncology Corporation, Santa Maria, CA; Pfizer Oncology, La Jolla, CA; Pfizer Oncology, New York, NY
| | - RA Dichmann
- 1University of California at Los Angeles, Los Angeles, CA; Irish Cooperative Oncology Research Group, Dublin, Ireland; Szent Margit Korhaz, Budapest, Hungary; National Institute of Oncology, Budapest, Hungary; Comprehensive Cancer Centers of Nevada, Henderson, NV; Comprehensive Blood and Cancer Center, Bakersfield, CA; University Hospital Mainz, Mainz, Germany; Suburban Hematology-Oncology Associates, Lawrenceville, GA; British Columbia Cancer Agency, Vancouver, BC, Canada; Petz Aladár Megyei Okato Korhaz, Gyor, Hungary; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy; Cancer Care Associates Medical Group, Redondo Beach, CA; Central Coast Medical Oncology Corporation, Santa Maria, CA; Pfizer Oncology, La Jolla, CA; Pfizer Oncology, New York, NY
| | - J Walshe
- 1University of California at Los Angeles, Los Angeles, CA; Irish Cooperative Oncology Research Group, Dublin, Ireland; Szent Margit Korhaz, Budapest, Hungary; National Institute of Oncology, Budapest, Hungary; Comprehensive Cancer Centers of Nevada, Henderson, NV; Comprehensive Blood and Cancer Center, Bakersfield, CA; University Hospital Mainz, Mainz, Germany; Suburban Hematology-Oncology Associates, Lawrenceville, GA; British Columbia Cancer Agency, Vancouver, BC, Canada; Petz Aladár Megyei Okato Korhaz, Gyor, Hungary; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy; Cancer Care Associates Medical Group, Redondo Beach, CA; Central Coast Medical Oncology Corporation, Santa Maria, CA; Pfizer Oncology, La Jolla, CA; Pfizer Oncology, New York, NY
| | - A Breazna
- 1University of California at Los Angeles, Los Angeles, CA; Irish Cooperative Oncology Research Group, Dublin, Ireland; Szent Margit Korhaz, Budapest, Hungary; National Institute of Oncology, Budapest, Hungary; Comprehensive Cancer Centers of Nevada, Henderson, NV; Comprehensive Blood and Cancer Center, Bakersfield, CA; University Hospital Mainz, Mainz, Germany; Suburban Hematology-Oncology Associates, Lawrenceville, GA; British Columbia Cancer Agency, Vancouver, BC, Canada; Petz Aladár Megyei Okato Korhaz, Gyor, Hungary; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy; Cancer Care Associates Medical Group, Redondo Beach, CA; Central Coast Medical Oncology Corporation, Santa Maria, CA; Pfizer Oncology, La Jolla, CA; Pfizer Oncology, New York, NY
| | - ST Kim
- 1University of California at Los Angeles, Los Angeles, CA; Irish Cooperative Oncology Research Group, Dublin, Ireland; Szent Margit Korhaz, Budapest, Hungary; National Institute of Oncology, Budapest, Hungary; Comprehensive Cancer Centers of Nevada, Henderson, NV; Comprehensive Blood and Cancer Center, Bakersfield, CA; University Hospital Mainz, Mainz, Germany; Suburban Hematology-Oncology Associates, Lawrenceville, GA; British Columbia Cancer Agency, Vancouver, BC, Canada; Petz Aladár Megyei Okato Korhaz, Gyor, Hungary; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy; Cancer Care Associates Medical Group, Redondo Beach, CA; Central Coast Medical Oncology Corporation, Santa Maria, CA; Pfizer Oncology, La Jolla, CA; Pfizer Oncology, New York, NY
| | - S Randolph
- 1University of California at Los Angeles, Los Angeles, CA; Irish Cooperative Oncology Research Group, Dublin, Ireland; Szent Margit Korhaz, Budapest, Hungary; National Institute of Oncology, Budapest, Hungary; Comprehensive Cancer Centers of Nevada, Henderson, NV; Comprehensive Blood and Cancer Center, Bakersfield, CA; University Hospital Mainz, Mainz, Germany; Suburban Hematology-Oncology Associates, Lawrenceville, GA; British Columbia Cancer Agency, Vancouver, BC, Canada; Petz Aladár Megyei Okato Korhaz, Gyor, Hungary; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy; Cancer Care Associates Medical Group, Redondo Beach, CA; Central Coast Medical Oncology Corporation, Santa Maria, CA; Pfizer Oncology, La Jolla, CA; Pfizer Oncology, New York, NY
| | - DJ Slamon
- 1University of California at Los Angeles, Los Angeles, CA; Irish Cooperative Oncology Research Group, Dublin, Ireland; Szent Margit Korhaz, Budapest, Hungary; National Institute of Oncology, Budapest, Hungary; Comprehensive Cancer Centers of Nevada, Henderson, NV; Comprehensive Blood and Cancer Center, Bakersfield, CA; University Hospital Mainz, Mainz, Germany; Suburban Hematology-Oncology Associates, Lawrenceville, GA; British Columbia Cancer Agency, Vancouver, BC, Canada; Petz Aladár Megyei Okato Korhaz, Gyor, Hungary; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy; Cancer Care Associates Medical Group, Redondo Beach, CA; Central Coast Medical Oncology Corporation, Santa Maria, CA; Pfizer Oncology, La Jolla, CA; Pfizer Oncology, New York, NY
| |
Collapse
|
37
|
Cotter M, Smyth E, Fitzpatrick F, Thomas T, Walshe J, Finn C, Duffy F, Morris-Downes M, Humphreys H. OB2.4 Vancomycin-resistant enterococci (VRE) in a neurosurgical unit; don't forget to look up! J Hosp Infect 2010. [DOI: 10.1016/s0195-6701(10)60031-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
38
|
Cotter M, Fitzpatrick F, Humphreys H, Thomas T, Walshe J, Moore J, Morris-Downes M, Smyth E. P23.03 Appropriate management of a Clostridium difficile ribotype 027 outbreak has long term effects in reducing Clostridium difficile associated diarrhoea. J Hosp Infect 2010. [DOI: 10.1016/s0195-6701(10)60218-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
39
|
Khan G, Treacy A, Garvey JP, Png B, Walshe J, Leader M, Byrne P. Ovarian inflammatory myofibroblastic tumour fistulating on to the anterior abdominal wall. J OBSTET GYNAECOL 2010; 30:74-6. [PMID: 20121520 DOI: 10.3109/01443610903315637] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Affiliation(s)
- G Khan
- Departments of Gynaecology, Beaumont Hospital, Beaumont, Dublin, Ireland.
| | | | | | | | | | | | | |
Collapse
|
40
|
Phelan P, O’Kelly P, O’Neill D, Little D, Hickey D, Keogan M, Walshe J, Magee C, Conlon P. Analysis of waiting times on Irish renal transplant list. Clin Transplant 2009; 24:381-5. [DOI: 10.1111/j.1399-0012.2009.01085.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
41
|
Martin P, Daniel SP, Conlon S, Walshe J, Grogan L. Primary Hepatic Lymphoma. Ir Med J 2005; 98:244-6. [PMID: 16255120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/05/2023]
|
42
|
Humphreys H, Dolan V, Sexton T, Conlon P, Rajan L, Creamer E, Walshe J, Donohoe J, Smyth EG. Implications of colonization of vancomycin-resistant enterococci (VRE) in renal dialysis patients. Learning to live with it? J Hosp Infect 2004; 58:28-33. [PMID: 15350710 DOI: 10.1016/j.jhin.2004.04.022] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2003] [Accepted: 04/16/2004] [Indexed: 12/12/2022]
Abstract
Vancomycin-resistant enterococci (VRE) commonly colonize, but less frequently infect, debilitated patients, such as those on chronic renal dialysis. The emergence of VRE amongst our cohort of renal replacement therapy patients posed considerable challenges in our attempts to prevent spread. Although 60 of 451 (13%) patients became colonized, only two patients required systemic antibiotics for confirmed or suspected invasive infection. Mortality and inpatient stay was greater in VRE-positive compared with VRE-negative patients (50% versus 10%) and patients who were screened on three or more occasions were likely to remain positive (e.g. 56% of patients screened on six occasions were positive). The application of recommended guidelines for the control of VRE, however, severely disrupted our renal dialysis programme and therefore had to be abandoned. As patients on renal dialysis are more likely to acquire VRE, remain colonized, require antibiotics and require regular inpatient or outpatient care more frequently than other patients, control measures should be adapted to minimize spread but not disrupt important and essential medical services.
Collapse
Affiliation(s)
- H Humphreys
- Department of Clinical Microbiology, Royal College of Surgeons in Ireland, Dublin, Ireland.
| | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Mason I, Chambers D, Shamim H, Walshe J, Irving C. Regulation and function of FGF8 in patterning of midbrain and anterior hindbrain. Biochem Cell Biol 2001; 78:577-84. [PMID: 11103948] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/18/2023] Open
Abstract
In this article, an adjunct to a platform presentation at the Winternational 2000 Symposium, we summarize the recent findings of this group concerning the regulation and functions of FGF8 expressed at the isthmus of the developing brain. We show that several different FGF8 isoforms, ectopically expressed in midbrain or posterior forebrain, are able to mimic the proliferative and patterning functions previously attributed to the isthmus in tissue grafting studies. Moreover, we also show that FGF8 protein is sufficient to induce an ectopic isthmic organiser (Fgf-8+, Gbx2+) in anterior midbrain. We also provide evidence that isthmic FGF8 patterns anterior hindbrain, repressing Hox-a2 expression and setting aside a territory of the brain that includes the cerebellar anlage. We show that these effects of FGF8 are likely to be mediated via FGFR1 and be modulated by the putative FGF antagonist, Sprouty2, identified using a differential display screen. Finally, we provide evidence that the onset of Fgf8 expression is regulated by En1 and that its expression at the isthmus is subsequently maintained by a specific and direct interaction between rhombomere 1 and midbrain.
Collapse
Affiliation(s)
- I Mason
- MRC Centre for Developmental Neurobiology, King's College London, UK.
| | | | | | | | | |
Collapse
|
44
|
Abstract
Studies involving chick embryos have implicated FGFs in neural induction and patterning as well as in other developmental events. Detailed analyses of FGF receptor expression at early stages of neural development have not been reported for the chick embryo and are incomplete for other vertebrate classes. Here we show the expression patterns of three FGF receptors, (FGFR1, FGFR2 and FGFR3) in embryonic stages between gastrulation and limb bud formation, focussing particularly on neural tissues. Between neural induction and neurulation, all three receptors are expressed in the neural plate albeit with distinct and overlapping distributions. During early neuromere formation FGFR1 transcripts are present throughout the neural tube, while transcripts for FGFR2 and FGFR3 become restricted to regions of the diencephalon and spinal cord. A little later, FGFR2 and FGFR3 are additionally expressed in the anterior midbrain and within the hindbrain. During later neuromere development, FGFR1 transcripts become localised to the telencephalon, anterior dorsal diencephalon and throughout the midbrain and hindbrain, whereas FGFR2 mRNA is restricted to dorsal telencephalon, dorsoanterior midbrain and hindbrain. FGFR3 is also expressed in anterior midbrain and hindbrain during this developmental period, and is additionally expressed in the posterior telencephalon, in the pretectum, and at the zona limitans intrathalamica. The observed expression patterns of all three receptors within the hindbrain, including rhombomere boundaries, are complex and dynamic. Expression patterns within the somites, eye, head mesenchyme, branchial arches, limb buds, nephric kidney and pharynx are also described.
Collapse
MESH Headings
- Animals
- Chick Embryo
- Embryo, Nonmammalian/embryology
- Embryo, Nonmammalian/physiology
- Gene Expression Regulation, Developmental
- Nervous System/embryology
- Protein-Tyrosine Kinases
- RNA, Messenger/biosynthesis
- RNA, Messenger/genetics
- Receptor Protein-Tyrosine Kinases/biosynthesis
- Receptor Protein-Tyrosine Kinases/genetics
- Receptor, Fibroblast Growth Factor, Type 1
- Receptor, Fibroblast Growth Factor, Type 2
- Receptor, Fibroblast Growth Factor, Type 3
- Receptors, Fibroblast Growth Factor/biosynthesis
- Receptors, Fibroblast Growth Factor/genetics
Collapse
Affiliation(s)
- J Walshe
- MRC Brain Development Programme, Centre for Developmental Neurobiology, King's College London, 4th Floor, New Hunt's House, Guy's Campus, London, UK
| | | |
Collapse
|
45
|
Thornton MJ, Thornton F, O'Callaghan J, Varghese JC, O'Brien E, Walshe J, Lee MJ. Evaluation of dynamic gadolinium-enhanced breath-hold MR angiography in the diagnosis of renal artery stenosis. AJR Am J Roentgenol 1999; 173:1279-83. [PMID: 10541105 DOI: 10.2214/ajr.173.5.10541105] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
OBJECTIVE The aim of our study was to evaluate a three-dimensional gadolinium-enhanced breath-hold MR angiography sequence using standard MR gradients in detecting renal artery stenosis. SUBJECTS AND METHODS Forty-two patients referred for angiography for suspected renal artery stenosis underwent both conventional digital subtraction angiography (DSA) and MR angiography. MR angiography was performed on a 1.5-T scanner with standard gradients. A fast multiplanar spoiled gradient-echo sequence was used with the following parameters: TR/TE, 10.3/1.9; flip angle, 45 degrees; field of view, 36 x 32 cm; matrix size, 256 x 128; one excitation; volume thickness, 70 mm; and partitions, 28. Gadolinium was administered IV as a dynamic bolus of 30-40 ml. Conventional and MR angiographic images were interpreted by two radiologists in consensus. RESULTS DSA revealed 87 renal arteries, of which 79 were in 35 patients with native kidneys and eight arteries were in seven patients with transplanted kidneys. Gadolinium-enhanced MR angiography showed 85 (98%) of 87 renal arteries. Seventeen patients had 20 significant (>50% stenosis) renal artery stenoses and five patients had five occluded renal arteries revealed by DSA. MR angiography revealed 85 renal arteries (98%), 20 stenoses (100%), and five occlusions (100%). Gadolinium-enhanced MR angiography led to one false-positive interpretation for renal artery stenosis and no false-negative interpretations. Thus, the sensitivity, specificity, and accuracy of MR angiography for renal artery stenosis were 100%, 98%, and 99%, respectively. CONCLUSION The MR angiography pulse sequence we used was an effective and reliable technique for the diagnosis of renal artery stenosis. The sequence can be performed on widely available MR equipment that does not require fast gradient hardware.
Collapse
Affiliation(s)
- M J Thornton
- Department of Radiology, Beaumont Hospital and Royal College of Surgeons in Ireland, Dublin
| | | | | | | | | | | | | |
Collapse
|
46
|
Thornton J, O'Callaghan J, Walshe J, O'Brien E, Varghese JC, Lee MJ. Comparison of digital subtraction angiography with gadolinium-enhanced magnetic resonance angiography in the diagnosis of renal artery stenosis. Eur Radiol 1999; 9:930-4. [PMID: 10369993 DOI: 10.1007/s003300050769] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
Renal artery stenosis (RAS) is a treatable cause of hypertension and renal failure for which no ideal screening technique is currently available. We evaluated the use of dynamic gadolinium-enhanced magnetic resonance angiography (MRA) for the diagnosis of RAS. Sixty-two patients with secondary hypertension were enrolled in the study. All patients had conventional renal angiography and gadolinium enhanced MRA. The sequence used was a 3D FMP SPGR sequence with the following parameters (TR: 26 ms, TE: 6.9 ms, flip angle 40 degrees, field of view 36 x 36 cm, matrix 246 x 256, 1 excitation). Gadolinium 0.3 mmol/kg was administered and 60 1. 5-mm-thick partitions were obtained over a duration of 3.5 min. The MRA images were then compared with conventional digital subtraction angiography (DSA) images. Conventional DSA demonstrated 138 renal arteries, whereas gadolinium-enhanced MRA demonstrated 129 (93 %). Twenty-one renal artery stenoses and four occluded arteries were seen at conventional DSA. Gadolinium-enhanced MRA had a sensitivity of 88 %, specificity of 98 %, accuracy of 96 %, positive predictive value of 92 % and negative predictive value of 97 % when compared with conventional DSA. Gadolinium-enhanced MRA is an accurate technique for identifying patients with RAS. It is less sensitive in picking up accessory renal arteries.
Collapse
Affiliation(s)
- J Thornton
- Department of Radiology Beaumont Hospital, Dublin 9, Ireland; and Royal College of Surgeons in Ireland, Dublin 2, Ireland
| | | | | | | | | | | |
Collapse
|
47
|
Abstract
BACKGROUND Clostridium difficile-associated diarrhoea (CDAD) is a potentially life-threatening illness which has been shown to be more common and more severe in patients with chronic renal failure (CRF) than in other groups. A review of CDAD in our nephrology unit was carried out. METHODS A review of microbiology and histology records identified 32 cases of CDAD in the nephrology unit over a 24-month period. Patient notes were reviewed to identify risk factors, clinical features and outcome. Available isolates of C. difficile underwent 16S ribosomal RNA typing. RESULTS The incidence of CDAD in the nephrology unit was 10.7 per 1000 admissions, compared to 2.7 per 1000 in other areas of the hospital (P<0.0001). CDAD was considered the sole or principal cause of death in six (19%) and was considered a contributing factor in a further seven (22%). Mortality was significantly higher among patients with established CRF (P=0.04). Seven cases occurred as a cluster, over a 1-month period. Isolates from this cluster, along with comparative strains from other areas of the hospital, were found to be PCR type 1. Diarrhoea occurred in 28 (89%) of cases, pyrexia in 17 (53%) and ileus or abdominal pain in 14 (44%). Six patients responded to discontinuation of antibiotics alone and 22 required metronidazole and/or vancomycin. Three patients had colectomy and one caecostomy because of toxic megacolon. Four patients died before specific therapy could be given and in two of these cases the diagnosis was made at autopsy. Twenty-six patients had a record of recent antibiotic therapy. Of these, 15 had at least one agent considered to be inappropriate (excessively broad spectrum agent in 11, excessive duration of therapy in four). Nine patients had only received antibiotics prior to admission. CONCLUSIONS CDAD carries a high mortality in nephrology patients, especially those with established CRF. The diagnosis may be missed if a careful antibiotic history is not taken, including agents received prior to admission. Rational antibiotic prescribing and adherence to infection control measures are vital to reduce the incidence of this serious condition.
Collapse
Affiliation(s)
- R J Cunney
- Department of Clinical Microbiology, Beaumont Hospital, Dublin, Ireland
| | | | | | | | | |
Collapse
|
48
|
Coakley R, O’Neill S, Coakley R, Glynn P, O’Neill S, Finlay GA, Russell KJ, McMahon K, D’Arcy EM, Masterson JB, Fitzgerald MX, O’Connor CM, O’Driscoll LR, Finlay GA, Fitzgerald MX, O’Connor CM, McGarvey LPA, Forsythe P, Heaney LG, MacMahon J, Ennis M, Leonard C, Tormey V, Burke CM, Poulter LW, Keatings VM, FitzGerald MX, Barnes PJ, Harty HR, Corfield DR, Adams L, Schwartzstein RM, Kiely JF, Buckley A, Shiels P, Deegan PC, Maurer B, McNicholas WT, Dunlop KA, Martin B, Riley M, Shields MD, Glynn P, Kilgallen I, Coakley R, O’Neill S, McElvaney NG, Cervantes-Laurean D, Wehr N, Gabriele K, Robinson W, Moss J, Levine RL, Urbach V, Walsh D, Harvey B, McElroy MC, Pittet JF, Allen L, Wiener-Kroonish J, Dobbs LG, O’Donnell DM, McMahon KJ, O’Connor C, Fitzgerald MX, McGuirk P, Mahon B, Griffin F, Mills KHG, Murphy R, Brijker F, Mulloy E, Cohen Tervaert JW, Walshe J, O’Neill S, McGarvey LPA, Heaney LG, Lowry RC, Shepherd DRT, MacMahon J, Gamble LA, Carton C, Memon R, Winter D, Chan A, Aherne T, O’Reilly P, Harbison JA, McNicholas WT, O’Callaghan S, Mulloy E, Keane M, McKenna M, Woods S, O’Neill S, Lamon A, Leonard C, Faul J, Murphy M, Burke CM, Tormey V, Riley M, Porszasz J, Engelen MPKJ, Brundage B, Wasserman K, Sweeney M, O’Regan RG, McLoughlin P, Sweeney M, Honner V, Sinnott B, O’Regan RG, McLoughlin P, Kilgallen I, O’Neill S, McGrath DS, Kiely J, Cryan B, Bredin CP, McGrath DS, Shortt C, Stack M, Kelleher N, Bredin CP, Russell KJ, McRedmond J, Mulkerji N, Keatings V, Fitzgerald MX, O’Connor CM, Boylan GM, McElroy MC, Dobbs LG, Forsythe P, McGarvey LPA, Cross LJM, Ennis M, Heaney LG, MacMahon J, Davern S, O’Connor CM, McDonnell TJ, Kiely JL, Lawless G, Cunningham S, McNicholas WT, Lordan J, Clancy L, Manning P, Plunkett P, Donaghy D, Kiely J, McDonnell TJ, Ben Musbah F, Loftus BG, Ben Musbah F, Loftus BG, Rutherford R, Watson SNE, Gilmartin JJ, Henry M, Mullins G, Brennan N, Kiely JL, Deegan PC, McNicholas WT. Irish thoracic society. Ir J Med Sci 1998. [DOI: 10.1007/bf02937212] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
49
|
Fawzy M, Harrison RF, Walshe J. Ovarian hyperstimulation syndrome: diagnosis, prevention and management. Ir Med J 1998; 91:86-7. [PMID: 9695426] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
|
50
|
Farrell J, Walshe J. About familial interstitial nephritis and retinis pigmentosa. Nephrol Dial Transplant 1998. [DOI: 10.1093/ndt/13.2.522-a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|